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ABSTRACT 
Amyotrophic Lateral Sclerosis (ALS) is an always lethal motor neuron disease with 
unknown pathogenesis.   Inhibitors of the molecular chaperone heat shock protein 90 
(Hsp90) have limited neuroprotection in some models of motor neuron degeneration.  
However the direct effect of Hsp90 inhibition on motor neurons is unknown.  Here we 
show that Hsp90 inhibition induced motor neuron death through activation of the P2X7 
receptor.  Motor neuron death required phosphatase and tensein homolog (PTEN)-
mediated inhibition of the PI3K/AKT pathway leading to Fas receptor activation and 
caspase dependent death.  The relevance of Hsp90 for motor neuron survival was 
investigated in mutant Cu/Zn superoxide dismutase (SOD) transgenic animal models for 
ALS. Nitrated Hsp90, a posttranslational modification known to induce cell death 
(Franco, Ye et al. 2013), was present in motor neurons after intracellular release of zinc 
deficient (Zn, D83S) and the SOD in which copper binding site was genetically ablated 
(Q) but not after copper deficient (Cu) wild type SOD.  Zn deficient and Q mutant SOD 
induced motor neuron death in a peroxynitrite mediated and copper dependent 
mechanism.  Nitrated Hsp90 was not detected in the spinal cord of transgenic animals for 
ALS-mutant SOD animal models until disease onset.  Increased nitrated Hsp90 
concentrations correlated with disease progression.  Addition of Zn or Q SOD to 
nontransgenic brain homogenate treated with peroxynitrite led to an increase level of 
nitrotyrosine in comparison to wild type controls.  However, in the same samples there 
was a 2 to 10 time increase in Hsp90 nitration as compared to nitrotyrosine.  The 
selective increase is likely due to the binding of Hsp90 to Zn deficient and Q SOD as 
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oppose to wild type SOD.  These results suggest that Hsp90 nitration facilitated by 
mutant SOD may cause motor neuron degeneration in ALS.  Targeted inhibition of 
nitrated Hsp90 may be a novel therapeutic approach for ALS.  An alternative therapeutic 
strategy is to target the production of survival factors by glial cells.  Riluzole is the only 
FDA approved drug for the treatment of ALS and it shows a small but significant 
increase in patient lifespan.  Our results show that acute riluzole treatment stimulated 
trophic factor production by astrocytes and Schwann cells.  However long-term exposure 
reversed and even inhibited the production of trophic factors, an observation that may 
explain the modest increase in patient survival in clinical trials.  Discontinuous riluzole 
treatment can maintain elevated trophic factor levels and prevent trophic factor reduction 
in spinal cords of nontransgenic animals.  These results suggest that discontinuous 
riluzole administration may improve ALS patient survival.  In summary, we 
demonstrated that Hsp90 has an essential function in the regulation of motor neuron 
survival.  We have also shown that Hsp90 was nitrated in the presence of mutant SOD 
and was present during symptom onset and increases as disease progresses, which may 
explain the toxic gain of function of mutant SOD.  Finally we demonstrate a biphasic 
effect of riluzole on trophic factor production and propose changes in administration to 
improve effects in ALS patients.  
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CHAPTER 1:  GENERAL INTRODUCTION 
Amyotrophic Lateral Sclerosis is an always-fatal neurodegenerative disease characterized 
by the loss of motor neurons in the motor cortex, brain stem and ventral spinal cord 
(Rossi, Franco et al. 2013).  It affects 2-3 in 100,000 people, with an average lifespan of 
2-5 years following diagnosis.  Approximately 10% of ALS cases are hereditary, or 
familiar, with an unknown pathological cause.  20-30% of the familiar form of ALS is 
linked to mutations in the superoxide dismutase (SOD) gene (Rosen, Siddique et al. 
1993; Wang, Sharma et al. 2008).  The identification of mutation in the gene of SOD 
allowed for the development of early transgenic mouse and rat models of ALS (Berthod 
and Gros-Louis 2012). 
The contribution of ALS-linked mutant SOD to disease onset and progression remains 
highly controversial.  Animals expressing mutant SOD in neuronal (Jaarsma, Teuling et 
al. 2008) or glial cells develop the disease phenotype (Papadeas, Kraig et al. 2011).  
Genetic deletion of SOD does not lead to disease (Reaume AG 1996) while cell-specific 
SOD knockout either delays disease onset or slows disease progression (Clement, 
Nguyen et al. 2003).  On the other hand, overexpression of wild type SOD has no effect, 
or accelerates disease progression (Bruijn, Houseweart et al. 1998; Deng, Shi et al. 2006). 
These seminal discoveries led to the hypothesis that mutant SOD contributes to ALS 
pathology by a toxic gain-of-function.  However the mechanism behind mutant SOD 
toxicity is still unknown.  
 2 
Disease progression in a G93A mutant SOD transgenic mouse model is well described.  
Muscular denervation of fast twitch muscle is detected by postnatal day 30 (p30) 
(Vinsant, Mansfield et al. 2013; Vinsant, Mansfield et al. 2013), but the animals are still 
considered asymptomatic by p60.  At p60, SOD aggregates can be observed and there is 
some compromised motor function (Bruijn, Becher et al. 1997).  During the early 
symptomatic stage (p90) there is extensive motor neuron death and dysfunction (Gurney, 
Pu et al. 1994; Bruijn, Becher et al. 1997).  Astrocytes (Barbeito, Pehar et al. 2004) and 
microglia (Liao, Zhao et al. 2012) are activated and nitrated proteins (Casoni, Basso et al. 
2005) are observed in both motor neurons and glial cells.  By end stage (p120), massive 
motor neuron loss is observed, slow twitch muscle are denervated and the myelin sheath 
is compromised (Vinsant, Mansfield et al. 2013; Vinsant, Mansfield et al. 2013).  In vivo, 
cell-specific SOD knockout in oligodendrocytes (Kang, Li et al. 2013), astrocytes 
(Yamanaka, Chun et al. 2008), and microglia slows disease progression where as 
neuronal specific knockout delays disease onset (Boillee, Yamanaka et al. 2006).  In 
vitro, conditioned media and co-culture experiments utilizing astrocytes overexpressing 
mutant SOD is toxic to motor neurons (Nagai, Re et al. 2007; Basso, Pozzi et al. 2013; 
Re, Le Verche et al. 2014).  This suggests a switch from secretion of pro-survival trophic 
factors to toxic factors from astrocytes.  Importantly, delivery of mutant SOD to pure 
motor neurons cultured in the presence of trophic factors induces cell death in a 
peroxynitrite and copper dependent mechanism (Estévez, Crow et al. 1999; Sahawneh, 
Ricart et al. 2010).  These findings reveal that both cell autonomous and non-cell 
autonomous mechanisms contribute to the pathology. 
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Riluzole is currently the only FDA approved drug for the treatment of ALS.  Riluzole has 
been shown to slightly extend lifespan of mutant SOD transgenic mice and ALS patients.  
However, it only extends lifespan in patients for three months to one year (Bensimon, 
Lacomblez et al. 1994; Gurney, Cutting et al. 1996; Lacomblez, Bensimon et al. 1996; 
Lacomblez, Bensimon et al. 1996; Gurney, Fleck et al. 1998).  Riluzole has been shown 
to stimulate glutamate reuptake, block sodium channels and stimulate trophic factor 
production by glial cells (Doble 1997; Peluffo, Estévez et al. 1997; Meininger, 
Lacomblez et al. 2000; Cheah, Vucic et al. 2010; Bellingham 2011; Dennys, Armstrong 
et al. 2015).  The primary mechanism of action was thought to be by preventing 
glutamate toxicity, but the development of other antiglutamates had no effect on ALS 
patient survival (Miller, Moore et al. 2001).  Consequently, the primary mechanism of 
action remains unknown.  Understanding the primary therapeutic effect of riluzole in 
ALS may lead to the development of new drugs or enhanced effectiveness of current 
therapies. 
The unknown underlying cause of ALS limits the development of therapeutically 
effective treatments.  This dissertation aims to advance the field of ALS in three ways:  
1. Identify critical molecular targets in the regulation of motor neuron survival  
2. Identify toxic gain of function of mutant SOD 
3. Improve effectiveness of current therapeutic strategies and identify novel 
therapeutic targets 
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CHAPTER 2: HSP90 IS CRITICAL FOR MOTOR NEURON 
SURVIVAL 
Introduction 
Heat shock protein (Hsp90) is a ubiquitous molecular chaperone that totals approximately 
1-2% of cytosolic proteins (Didelot, Schmitt et al. 2006).  Hsp90 participates in the 
regulation of a variety of pro-survival cellular processes through interactions with more 
than 200 client proteins, including numerous transcription factors and kinases such as 
phosphatidyl inositol-3 kinase (PI3K), phosphoinositide-dependent kinase-1 (PDK1) and 
Akt (Pearl and Prodromou 2000; Richter and Buchner 2001; Picard 2002; Pratt and Toft 
2003; Whitesell and Lindquist 2005; Zhao, Davey et al. 2005; Gaestel 2006; Pearl and 
Prodromou 2006; Pratt, Morishima et al. 2008; Mollapour and Neckers 2011; Li and 
Buchner 2013). In most cells, alteration of the interaction of Hsp90 with the transcription 
factor heat shock factor 1 (HSF1) results in the expression of stress proteins such as heat 
shock protein 70 and 40 (Hsp70 and Hsp40) (Richter, Haslbeck et al. 2010; Robinson, 
Gifondorwa et al. 2010).  However, motor neurons do not have a typical stress response 
and fail to induce the expression of Hsp70 (Newbern, Taylor et al. 2005), a condition that 
is reversed by HSF1 overexpression (Batulan, Taylor et al. 2006).  These results suggest 
that motor neurons have a higher threshold for the induction of the heat shock response 
(Batulan, Shinder et al. 2003; Batulan, Taylor et al. 2006).  In contrast, in the same 
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conditions astrocytes induce and release Hsp70, which is a survival factor for motor 
neurons (Robinson, Tidwell et al. 2005; Taylor, Gifondorwa et al. 2007).  
The benzoquinone ansamycin antibiotic geldanamycin, is a specific inhibitor of Hsp90 
that binds to the unusual ATPase binding site within the N-terminus domain of the 
chaperone inhibiting its ATPase activity (Prodromou, Roe et al. 1997; Stebbins, Russo et 
al. 1997).  Inhibition of Hsp90 using geldanamycin in dissociated spinal cord cultures 
stimulates the expression of Hsp40 and Hsp70 by motor neurons and prevents mutant 
SOD-dependent motor neuron death (Batulan, Taylor et al. 2006). Hsp90 inhibition 
prevents also glutamate toxicity in a mouse hippocampal cell line (Xiao, Callaway et al. 
1999).  However, inhibition of Hsp90 also activates the heat shock response in astrocytes, 
leading to the release of Hsp70 and subsequent uptake by motor neurons, which improves 
motor neuron survival (Taylor, Gifondorwa et al. 2007). Therefore it remains to be 
determined whether the protection afforded by Hsp90 inhibitors is due to direct effects on 
motor neurons. Here, we investigated the direct effects of Hsp90 inhibition on purified 
motor neurons cultures. Pure motor neurons were 10-1000 times more susceptible to 
inhibition of Hsp90 by geldanamycin than any other cell type tested. Inhibition of Hsp90 
triggered motor neuron death by the P2X7 receptor-dependent activation of PTEN, 
leading to inhibition of the pro-survival PI3K/Akt pathway and activation of the Fas 
death pathway. 
 6 
Materials and Methods 
Motor neuron cell culture:  Motor neurons were prepared as previously described 
(Henderson, Bloch-Gallego et al. 1995; Raoul, Henderson et al. 1999; Franco, Ye et al. 
2013).  Briefly, isolated ventral spinal cords from E15 rat embryos were trypsinized and 
the tissue disaggregated by trituration.  The cell suspension was centrifuged on top of a 
6% OptiPrep cushion (Sigma, Saint Louis, MO) and the motor neurons were removed 
from the interface.  Motor neurons were further purified by magnet-assisted cell 
separation (Miltenyi Biotec, Auburn CA) using an antibody against p75 low-affinity 
neurotrophin receptor (Chemicon-Milliport, Billerica, MA).  Motor neurons were plated 
on 96 well plates (750 cells per well), 35 mm plates (20,000 cells per plate, with the 
exception of 100,000 cells per plate for western blots for FOXO3a), 4-well plates (3,000 
cells per well), or 8-well chamber slides (30,000 cells per well) coated with poly-DL-
ornithine and laminin (Sigma). Motor neurons were maintained in neurobasal media 
supplemented with B27, heat inactivated horse serum, glutamine, glutamate, 3-
mercaptoethanol (all from Gibco/Invitrogen, Carlsbad, CA) and trophic factors (1 ng/ml 
BDNF, 0.1 ng/ml GDNF, 10 ng/ml cardiotrophin-1), and incubated in a 5% CO2 
humidified atmosphere at 37°C. 
Cortical neuron cell culture:  Cortical neurons were obtained from the cerebral cortex of 
fetal Sprague Dawley rats (E17) by a papain dissociation method as described previously 
(Gonzalez-Zulueta, Ensz et al. 1998). Cultures were plated on poly-D-lysine (Sigma-
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Aldrich)-coated cell culture dishes and maintained in minimum essential medium (MEM) 
(Invitrogen, Grand Island, NY) containing 5.5 g/L glucose, 2 mM glutamine, 100 µM 
cystine, and supplemented with 10% fetal bovine serum (FBS; Invitrogen) and 1% 
penicillin/streptomycin (Invitrogen).  Cultures plated at a low density (10,000 cells/ml) 
were maintained in MEM containing 10% horse serum (HS; Invitrogen) instead of FBS 
and 10 M BHA (Invitrogen). All experiments were initiated 24 h after plating. 
NSC34 cell culture:  NSC34 motor neuron hybrid line was maintained in DMEM 
containing 10% FBS and 1% Penicillin/Streptomycin at 37◦C during the growth stage.  
To differentiate the cells, 10% HS was substituted for FBS and 1 µM retinoic acid was 
added.  The cells were differentiated for a period of one week prior to treatments.   
Motor neuron survival:  Motor neuron survival was determined either by counting by 
hand in four well plates (Nunc) or by calcein staining (Molecular Probes, Invitrogen) for 
45 minutes in black 96-well plates (Greiner Bio-One, Monroe, NC) as previously 
described (Franco, Ye et al. 2013). Extracellular calcein was quenched with 100 mg/mL 
hemoglobin and the images were captured using the RUNNER (Trophos, Marseilles, 
France).  Cell counts were obtained using the Tina software (Trophos). Cell counts are 
represented as percent survival relative to the survival of neurons in the presence of 
neurotrophic factors alone. 
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Immunofluorescence:  Motor neurons were plated in 4-well chamber slides and fixed in 
paraformaldehyde and processed for immunofluorescence (Franco, Ye et al. 2013).  Cells 
were briefly prefixed with 4% paraformaldehyde (PFA) and 0.1% glutaraldehyde in same 
volume of original media for 2 minutes on ice.  Cells were rinsed 3 times with PBS 
containing magnesium and calcium and incubated for 20 minutes with 4% PFA and 0.1% 
glutaldehyde.  Cells were then incubated with anti-mouse in 4% goat serum for 1 hr to 
block the purification antibody and fixed with 4% PFA and 0.1% glutaldehyde for 15 
minutes.  After rinsing with PBS, cells were incubated with 50 mM glycine and 0.2% 
Triton X-100 in PBS for 30 minutes at room temperature.  Cells were then incubated with 
signal enhancer (Invitrogen) for 30 minutes room temperature.  Cells were blocked using 
4% goat serum and 0.2% Triton X-100 at room temperature for 1 hour.  Primary 
antibodies, FoxO3a (Cell Signaling) and MAP2 (Sigma) were incubated in blocking 
solution in a humidified chamber at 4C overnight and then rinsed 3 times with PBS.  
Cells were incubated with fluorescent secondary antibodies [AlexaFluor 594 donkey anti-
mouse IgG and AlexaFluor 488 donkey anti-rabbit (Invitrogen)] for 1 hour at room 
temperature protected from light.  Cells were then stained with DAPI and rinsed three 
times with PBS and once with water once before being mounted using ProLong Gold 
(Molecular Probes, Invitrogen, Eugene, OR). 
Microscopy: Immunoflourescence was imaged using Carl Zeiss Observer A1 with 
AxioVision 2010 acquisition software.  All images were taken using a Zeiss oil 
immersion, 63X/1.40 Plan Apochromat objective (#420781-9910). Image acquisition for 
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each channel (exposure, brightness, contrast and gamma) was taken at the same settings 
for each image.  Brightness was adjusted in the Zen software post-acquisition to produce 
the best image possible and was set to the same levels across experimental groups. 
Immunoblotting:  Cells were lysed using a NP-40 lysis buffer (1% NP-40, 40 mM Tris, 
pH 7.4, 0.15 M NaCl, 10% glycerol, 0.1% SDS, 0.1% deoxycholate) or RIPA buffer 
(25mM Tris-HCl (pH 7.6), 150mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% 
SDS) containing protease and phosphatase inhibitors.  Cells were subjected to sonication 
or freeze-thaw and then centrifuged to collect supernatant.  Lysate was separated by SDS-
PAGE before transfer to PVDF membrane.  After blocking with Odyssey Blocking 
Buffer (LI-COR Biosciences), membranes were incubated with primary antibodies 
overnight at 4C, washed, incubated with secondary antibodies for 1 h at room 
temperature, washed, and scanned. The LI-COR Biosciences Odyssey Infrared Imaging 
system was used to visualize blots.  Secondary antibodies were obtained from LI-COR 
Biosciences (IR 680 goat anti-rabbit IgG and IR 800 goat-anti-mouse IgG or 680 donkey 
anti-rabbit and 700 donkey anti goat).  Primary antibodies were the following:  Akt, pAkt 
(Ser473), pAKT (thr308), FoxO3a, pPDK1 (Ser 241) and Myc from Cell Signaling, FasL 
(N-20) from Santa Cruz, and PDK1 from BD Biosciences.  Bands were quantified using 
ImageJ software. 
Quantitative RT-PCR:  RNA was extracted and purified using the Trizol-based PureLink 
RNA kit (Invitrogen).  The cDNA was synthesized using SuperScript First-Strand 
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Synthesis (Invitrogen).  Real-time PCR was performed using the 7500 Fast Real-Time 
PCR System and SDS software (Applied Biosystems).  TaqMan Fast Universal PCR Mix 
and TaqMan fluorescent probes for Fas ligand, Fas receptor, GAPDH, and -actin were 
obtained from Applied Biosystems.   
Adenoviral vectors construction:  The p110-CAAX subunit of PI3K, A280V PDK1 and 
N-term myristolyation AKT1 were cloned separately into pAdTrack-CMV using 
restriction enzymes SalI and EcoRV (Genscript Corporation, Piscataway, NJ).  The 
adenoviral vectors were prepared and amplified as previously described (He, Zhou et al. 
1998). Briefly, the linear vectors were electroporated in chemically competent cells 
containing pAdEasy1. The resulting adenoviral vector co-expressing GFP was digested 
with Pac1 and transfected into HEK293A cells using Lipofectamine 2000 (Invitrogen).  
The infected cells were cultured until all cells were GFP positive, at which time cells 
were lifted and lysed by freeze/thaw.  The viral stock was then amplified to a titer of 
1x10
-8
. 
Motor neuron transduction:  Purified motor neurons (80 motor neurons/μl) were 
incubated with the adenoviral vectors at a multiplicity of infection of 120 for 2 hours at 
4°C in transduction media (1% heat inactivated fetal bovine serum, 20 μM glucose, 0.5 
μg/mL insulin, 10 μM putrescine, 10 μg/mL conalbumin, and 0.3 nM sodium selenite, 20 
nM progesterone).  Motor neurons were then plated at a density of 3,000 cells/well in a 4 
well plate and cultured for 72 h at 37°C, 5% CO2/air prior to experimentation.                                            
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Luciferase assay:  Motor neurons were plated for 2 hours before being transduced (MOI 
160) with a lentivirus producing luciferase under the control of the forkhead responsive 
element (Qiagen).  The following day, motor neurons were treated with 0.5 nM 
geldanamycin for 16 hours.  Cells were lysed with the Promega One-Glo luciferase kit 
and luminescence was measured on a microplate reader for 10 seconds.  
Statistical analysis: Graphing and statistical analysis was performed using Prism software 
(Graphpad).  Multiple comparisons were performed using one or two-way ANOVA, 
followed by the Bonferroni multiple comparison test or student T-test.  Survival and dose 
response data were fit to a sigmoidal curve.  Values were considered significantly 
different when p < 0.05.  All experiments were performed in triplicate.  
Results 
Motor neurons are highly sensitive to inhibition of Hsp90.  The effect of Hsp90 inhibition 
on motor neuron survival was assessed in pure motor neuron cultures incubated with 
increasing concentrations of the Hsp90 inhibitor geldanamycin and in the presence or 
absence of trophic factors. Motor neurons cultured in the presence of trophic factors with 
geldanamycin for 24 h were 10 times more sensitive to Hsp90 inhibition than the motor 
neurons that survived without trophic factors and incubated with geldanamycin for 24 h 
(Fig. 1A and B).  The sensitivity of pure motor neurons to Hsp90 inhibition was 
investigated by comparing the EC50 of geldanamycin-induced motor neuron death to that 
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of cultures of dissociated embryo ventral spinal cord and cortical neurons at low and high 
density (Fig. 1C and D), and undifferentiated and differentiated cultures of the hybrid 
motor neuron cell line NCS34 (Fig. 1E).  The EC50 of purified motor neurons cultured in 
the presence of trophic factors was between 10-10,000 times lower than the equivalent 
value for all other cell types (Table 1).  This sensitivity was not due to variations in 
overall levels of Hsp90 in motor neurons (Fig. 1F and G).  Thus, inhibition of Hsp90 
induces motor neuron death and the vulnerability of motor neurons to Hsp90 inhibition is 
enhanced by activation of trophic signaling pathways. These results suggest that motor 
neurons are more sensitive to inhibition of Hsp90 due to activation of a specific cell 
death-signaling pathway not present in other cell types or because motor neurons are 
more sensitive to the inhibition of a critical pro-survival pathway. 
Inhibition of Hsp90 activates the Fas receptor/FasL pathway.  Motor neurons cultured in 
the presence of trophic factors were an order of magnitude more sensitive to inhibition of 
Hsp90 than motor neurons deprived of trophic factors (Table 1), suggesting that 
inhibition of Hsp90 may activate the same cell death pathway induced by trophic factor 
deprivation. Trophic factor deprivation leads to the activation of the Fas pathway and 
subsequent motor neuron apoptosis (Raoul, Henderson et al. 1999; Raoul, Estévez et al. 
2002). Indeed, incubation of motor neurons with 0.5 nM geldanamycin in the presence of 
the Fas ligand (FasL) decoy Fas:FC completely prevented motor neuron death (Fig. 2A). 
However, Fas:Fc only shifted the EC50 for geldanamycin toxicity to values comparable to 
those of trophic factor deprivation (EC50: 4.8 nM, 95% CI: 3.5 nM
 
to 6.5 nM, Fig. 2B). 
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This observation reveals the existence of a Fas-independent cell death pathway triggered 
at higher concentrations of geldanamycin were Fas:FC is only partially protective. 
Transcription and translation of FasL is necessary for the activation of Fas-mediated 
apoptosis in trophic factor deprived motor neurons or motor neuron carrying amyotrophic 
lateral sclerosis (ALS)-linking mutant superoxide dismutase (SOD) in the presence of 
nitric oxide (Raoul, Henderson et al. 1999; Raoul, Estévez et al. 2002).  Inhibition of both 
transcription and translation prevented geldanamycin-induced apoptosis (Fig. 2C), 
suggesting that geldanamycin-induced motor neuron death required de novo protein 
synthesis.  Indeed, the expression of the FasL messenger RNA was stimulated 18 h after 
Hsp90 inhibition (Fig. 2D), without affecting the expression of Fas receptor (Fig. 2E).  
These results suggest that in the presence of trophic factors, Hsp90 activity is essential to 
motor neuron survival. 
In motor neurons, stimulation of the DAXX component of the Fas pathway leads to 
activation of p38-MAP kinase, expression of neuronal nitric oxide synthase (nNOS) and 
production of peroxynitrite (Raoul, Estévez et al. 2002).  To investigate the role of the 
DAXX component of the Fas pathways in the induction of apoptosis, motor neurons were 
incubated with geldanamycin and the NOS inhibitor, L-NAME.  Inhibition of NOS did 
not prevent geldanamycin-induced motor neuron death, but it did prevent cell death 
stimulated by trophic factor deprivation (Fig. 3A).  Production of 80-120 nM steady state 
concentrations of nitric oxide did not affect geldanamycin-induced motor neuron death 
(Fig. 3B).  Similarly, incubation of motor neurons with 0.5 nM geldanamycin in the 
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presence of the SOD mimetic, MnTBAP, and the superoxide and peroxynitrite scavenger, 
FeTCPP, did not prevent motor neuron death. However, MnTBAP and FeTCPP at the 
same concentrations prevented apoptosis induced by trophic factor deprivation (Fig. 3C).  
Inhibition of p38 also failed to prevent motor neuron death induced by inhibition of 
Hsp90 (Fig. 3D).  Motor neuron death downstream of Fas receptor activation may also 
occur independently of peroxynitrite production by stimulation of the FADD component 
of the Fas pathway involving the activation of caspases (Raoul, Estévez et al. 2002; 
Franco, Ye et al. 2013). Indeed, the pan caspase inhibitor z-VAD and selective inhibitors 
for caspases 3, 8, and 9 prevented geldanamycin-induced motor neuron death (Fig. 2F).  
Together, these results reveal that inhibition of Hsp90 stimulates motor neuron apoptosis 
by a Fas-dependent and peroxynitrite-independent mechanism. 
Hsp90 inhibition induces FOXO3a dependent transcription.  FasL expression in motor 
neurons is mediated by the activation of forkhead box 03 (FOXO3a) (Barthelemy, 
Henderson et al. 2004). Activation of FOXO3a is stimulated by dephosphorylation of 
ser253 (Brunet, Bonni et al. 1999; Tang, Nunez et al. 1999).  Incubation of motor neurons 
with geldanamycin reduced the phosphorylation levels of FOXO3a, with no change in 
total levels of the transcription factor (Fig 4A-C).  Consequently, FOXO3a translocated 
to the nucleus after inhibition of Hsp90 (Fig. 4D).  The activity of FOXO3a was 
measured by transducing motor neurons with a reporter construct carrying luciferase 
under the control of the forkhead responsive element (FHRE).  There was a two fold 
increase in the luciferase activity of motor neurons incubated with geldanamycin for 16 h 
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compared to untreated controls (Fig. 4E). No changes in cell number were detected after 
16 h incubation with geldanamycin (Fig. 4F), revealing that inhibition of Hsp90 activates 
FOXO3a-dependent transcription.  
Hsp90 inhibition leads to PTEN-mediated inhibition of the PI3K/Akt pathway upstream 
of Fas receptor activation.  Inhibition of the PI3K pathway leads to translocation of 
FOXO3a to the nucleus (Mojsilovic-Petrovic, Nedelsky et al. 2009).  Downstream of 
PI3K, PDK1 and Akt are Hsp90 clients (Sato, Fujita et al. 2000; Basso, Solit et al. 2002; 
Fujita, Sato et al. 2002).  To investigate whether inhibition of the PI3K pathway led to the 
induction of Fas-dependent apoptosis, motor neurons were incubated with the PI3K 
inhibitors LY294002 and wortmannin in the presence or absence of Fas:Fc and in the 
presence of trophic factors.  Fas:Fc prevented LY294002 and wortmannin-induced motor 
neuron death (Fig. 5), suggesting that in the presence of trophic factors, activation of the 
PI3K pathway prevents Fas-induced motor neuron death. Incubation of motor neurons 
with geldanamycin reduced phosphorylation of Akt at Ser 473 after 18 and 24 hours (Fig. 
6A) with a smaller but faster decrease in phosphorylation at Thr 308 (Fig. 6B) and no 
change in total Akt (Fig. 6C).  These results suggest that geldanamycin does not affect 
the formation of the complex Hsp90/Akt, which will result in a decrease in total Akt 
(Sato, Fujita et al. 2000).  In addition, inhibition of Hsp90 did not affect PDK1 
intracellular levels (Fig. 6D).  Expression of constitutively active Akt1, PDK1, and PI3K 
in motor neurons using adenoviral vectors prevented geldanamycin-induced motor 
neuron death (Fig. 7A and B). These results suggest that inhibition of Hsp90 prevents the 
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activation of the PI3K/Akt pro-survival pathway upstream of PI3K activation, ultimately 
leading to activation of the Fas/FasL pathway.   
The phosphatase and tensin homolog (PTEN) inhibits the PI3K/Akt pathway by 
dephosphorylating phosphatidyl-inositol,3,4,5 triphosphate (PIP3) to 
phosphatidylinositol-3,4-diphosphate (PIP2), thus preventing the activation of PDK1 
(Weng, Brown et al. 2001; Jiang and Liu 2008). Pharmacological inhibition or down-
regulation of PTEN prevented induction of motor neuron death by geldanamycin (Fig. 7C 
and 7D).  These results reveal that stimulation of PTEN by inhibition of Hsp90 prevents 
activation of PDK1, decreasing Akt activity and triggering motor neuron death. 
Hsp90 inhibition activates P2X7 receptor.  Hsp90 is a negative regulator of the P2X7 
ionotropic ATP-gated receptor (Adinolfi, Kim et al. 2003). Activation of P2X7 receptor 
stimulates an influx of calcium that triggers motor neuron death through the activation of 
the Fas pathway (Franco, Ye et al. 2013; Gandelman, Levy et al. 2013). Inhibition of the 
P2X7 receptor with brilliant blue G or down-regulation using siRNA prevented motor 
neuron death stimulated by Hsp90 inhibition. The intracellular calcium chelator BAPTA-
AM also prevented motor neuron death stimulated by inhibition of Hsp90 (Fig. 8). To 
determine whether Hsp90 inhibition was derepressing P2X7 receptor or stimulating the 
release of ATP, motor neurons were incubated with geldanamycin in the presence of the 
ATP-degrading enzyme apyrase.  Incubation with apyrase did not affect geldanamycin-
 17 
induced motor neuron death (Fig. 8), suggesting that inhibition of Hsp90 activates P2X7 
receptor independently of its ligand ATP.   
Discussion 
P2X7 receptor stimulates motor neuron apoptosis by a Fas-dependent pathway (Franco, 
Ye et al. 2013; Gandelman, Levy et al. 2013).  Furthermore, phosphorylated Hsp90 is a 
negative regulator of P2X7 receptor (Adinolfi, Kim et al. 2003).  In agreement with a 
negative role on P2X7 receptor activation, motor neuron death induced by Hsp90 
inhibition was prevented by both P2X7 receptor inhibition and down regulation of its 
expression.  The Hsp90 associated to the P2X7 receptor complex seems to be very 
sensitive to inhibition by geldanamycin. Concentrations of geldanamycin in the 
picomolar range were sufficient to stimulated motor neuron death.  In contrast, activation 
of the heat shock response in motor neurons requires higher concentrations of 
geldanamycin (Batulan, Shinder et al. 2003; Robinson, Tidwell et al. 2005).  In fact 
motor neurons have an atypical heat shock response (Batulan, Shinder et al. 2003; 
Robinson, Tidwell et al. 2005).  In normal conditions, HSF1 is kept in the cytoplasm by a 
complex that includes Hsp90 and Hsp70 (Richter, Haslbeck et al. 2010; Robinson, 
Gifondorwa et al. 2010).  As a consequence of protein unfolding or inhibition of Hsp90 
the complex dissociates releasing HSF1, which migrates to the nucleus and activates the 
expression of proteins associate with the stress response (Richter, Haslbeck et al. 2010; 
Robinson, Gifondorwa et al. 2010).  Motor neurons have a high threshold for the 
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activation of the HSF1, which leads to a deficient stress response (Batulan, Shinder et al. 
2003; Batulan, Taylor et al. 2006; Robinson, Gifondorwa et al. 2010). We found that 
highly purified motor neuron cultures incubated with trophic factors are abnormally 
sensitive to Hsp90 inhibition.  The high sensitivity was not due to differential expression 
of Hsp90 respect to other cell types or tissues, but rather it seems to be characteristic of 
motor neurons.  The affinity of geldanamycin and ATP for Hsp90 depends on post-
translational modifications and the interaction with client proteins and co-chaperones 
(Fiskus, Rao et al. 2008; Rao, Fiskus et al. 2008; Mahalingam, Swords et al. 2009; 
Walton-Diaz, Khan et al. 2013).  Post-translational modifications and co-chaperons affect 
also the affinity of Hsp90 for client proteins (Pearl and Prodromou 2006; Mollapour, 
Tsutsumi et al. 2010; Li and Buchner 2013; Walton-Diaz, Khan et al. 2013).  The 
combination of post-translational modifications and protein interactions of Hsp90 in the 
P2X7 complex in motor neurons may provide the conditions that make the chaperone 
exceptionally sensitive to geldanamycin inhibition. It is also possible that the same 
conditions that conferred a high threshold for the activation of the stress response are 
responsible for the high sensitivity to Hsp90 inhibition in motor neurons.  However, there 
are clear differences on the effects of geldanamycin previously reported and our results, 
which can be explained by the different condition used to culture the motor neurons.  The 
presence of other cells like astrocytes in the culture can mask direct effects of Hsp90 
inhibition on motor neurons (Robinson, Tidwell et al. 2005; Robinson, Gifondorwa et al. 
2010).   
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Motor neurons are highly dependent on the supply of trophic factors for survival both in 
culture and in vivo (Sendtner, Arakawa et al. 1991; Oppenheim, Yin et al. 1992; 
Henderson, Camu et al. 1993). The protection provide by trophic factors is due to 
activation of the PI3K/Akt pathway.  Indeed, motor neurons are highly dependent on the 
activity of the PI3K/Akt pathway and inhibition of this pathway stimulates death by 
apoptosis (Milligan, Prevette et al. 1995; Li, Prevette et al. 1998; Dolcet, Egea et al. 
1999; Raoul, Henderson et al. 1999; Soler, Dolcet et al. 1999; Garces, Haase et al. 2000).  
PDK1 and Akt are known clients of Hsp90.  Hsp90 has the double function of preventing 
the degradation of the activated kinase, and through the binding of co-chaperones 
participates in directing the kinases to their targets (Basso, Solit et al. 2002; Fujita, Sato 
et al. 2002).  Inhibition of Hsp90 in motor neurons down-regulated the PI3K/Akt 
pathway as determined by decreased Akt phosphorylation (Fig 6).  Consistent with this 
interpretation, overexpression of constitutive active PDK1 and Akt prevented motor 
neuron death induced by inhibition of Hsp90.  However, overexpression of the p110 
constitutive active catalytic subunit of the PI3K also prevented motor neuron apoptosis 
induced by inhibition of Hsp90 (Fig. 7).  To the best of our knowledge, PI3K is not a 
client of Hsp90, suggesting that Hsp90 inhibition is acting upstream of this kinase.  
Inhibition of PTEN, a well-known down regulator of the PI3K/Akt pathway has recently 
been shown to improve motor neuron survival and function in cell culture and in vivo 
models of motor neuron degeneration (Ning, Drepper et al. 2010; Kirby, Ning et al. 2011; 
Yang, Wang et al. 2014). PTEN inhibits PDK1 activation by catalyzing the 
dephosphorylation of phosphatidylinositol 3,4,5 triphostate (PIP3) to phosphatidylinositol 
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3,4 biphosphate (PIP2) (Fig. 9).  Low levels of PIP3 prevent the activation of PDK1, 
inhibiting the activation of Akt and its down-stream cell signaling (Jiang and Liu 2008).  
In addition, PTEN is activated downstream of P2X7 (Mistafa, Ghalali et al. 2010; 
Miraglia, Hogberg et al. 2012; Ghalali, Wiklund et al. 2014).  Consistent with activation 
of PTEN downstream of P2X7, inhibition of the phosphatase blocked geldanamycin 
toxicity (Fig. 7). In normal conditions, the over-activation of PI3K probably overwhelms 
the capacity of PTEN to decrease the levels of PIP3, keeping the pathway active and the 
motor neurons alive.   
Trophic factor deprivation triggers Fas-dependent motor neuron apoptosis through the 
activation of two different pathways downstream of Fas receptor, a DAXX-dependent 
and a FADD-dependent pathway (Raoul, Henderson et al. 1999; Raoul, Estévez et al. 
2002).  While the DAXX-dependent pathway induces peroxynitrite production, the 
FADD-dependent component ultimately activates the cell death effector caspase 3. Our 
results show that depending on the concentration of inhibitor, inhibition of Hsp90 
stimulated two different cell death mechanisms.  In the presence of trophic factors, low 
concentrations of geldanamycin stimulated Fas-dependent apoptosis, while high 
concentrations also triggered Fas-independent motor neuron death (Fig. 2). The EC50 for 
the induction of motor neurons death by geldanamycin in the presence of trophic factors 
and Fas:Fc, a condition in which the Fas pathway is inhibited, was the same as the EC50 
for the induction of death of trophic factor-deprived motor neurons. This observation 
provides further support to the conclusion that trophic factor deprivation and low 
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concentrations of geldanamycin stimulate the same death pathways in motor neurons. 
However, inhibition of Hsp90 did not require peroxynitrite production, as is the case for 
trophic factor deprivation (Estevez, Spear et al. 1998; Estevez, Sampson et al. 2000; 
Raoul, Estévez et al. 2002). Inhibitors of nitric oxide production and scavengers of 
superoxide and peroxynitrite had no effect on geldanamycin-induced motor neuron death 
(Fig. 3).  We have recently identified Hsp90 as a target for peroxynitrite nitration. 
Nitrated Hsp90 triggers motor neuron apoptosis through the activation of the FADD 
component of the Fas pathway that is independent of peroxynitrite formation (Franco, Ye 
et al. 2013). Indeed, activation of the DAXX component of the pathway leads to 
peroxynitrite formation, nitration of Hsp90 and subsequent activation of the FADD-
dependent pathway, inducing motor neuron apoptosis (Franco, Ye et al. 2013). The 
results showed here support the notion that both nitrated Hsp90 and inhibition of Hsp90 
act downstream of peroxynitrite formation in the motor neuron death pathway.  Both 
pathways are mediated by P2X7 and Fas activation.  However, there are some differences 
between both mechanisms; while nitrated Hsp90-induced apoptosis is independent of 
gene expression and protein synthesis, geldanamycin-induced motor neuron death 
requires de novo synthesis of Fas ligand, as previously described for trophic factor 
deprivation (Raoul, Henderson et al. 1999; Barthelemy, Henderson et al. 2004). One very 
important difference between the two models is that nitrated Hsp90 stimulates cell death 
by a gain-of-function, while induction of motor neuron death by geldanamycin is due to a 
loss-of-function, which may explain the differences in the activation of the pathways. In 
spite of the differences, the requirement for P2X7 activation in both conditions suggests 
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that the inhibition of the purine receptor by Hsp90 is key for motor neuron survival.  This 
inhibition seems to be easily perturbed by post-translational modifications or inhibition of 
the chaperone. 
The nuclear factor FOXO3a regulates the expression of Fas ligand and several other pro-
apoptotic proteins, including Bim (Barthelemy, Henderson et al. 2004; Behzad, Jamil et 
al. 2007). The activity of FOXO3a is negatively regulated by Akt activation, which 
results in retention of the factor in the cytoplasm (Brunet, Bonni et al. 1999; Tang, Nunez 
et al. 1999; Barthelemy, Henderson et al. 2004). Inactivation of the PI3K/Akt pathway by 
inhibition of Hsp90 prevented the phosphorylation of FOXO3a, allowing its activation, 
translocation to the nucleus (Fig. 4) and expression of Fas ligand. However, translocation 
of FOXO3a to the nucleus can also be neuroprotective in mixed spinal cord cultures. 
Overexpression of a constitutively active FOXO3a or treatment of motor neurons with 
psammaplysene, which reduces phospho-FOXO3a levels with no effect on AKT 
phosphorylation, effectively prevent motor neuron death induced by a number of noxious 
stimuli.  However, direct inhibition of PI3K does not improve survival of motor neurons 
containing mutant SOD (Mojsilovic-Petrovic, Nedelsky et al. 2009). Our results are in 
agreement with a number of previous publications showing that inhibition of the PI3K 
pathway, which stimulates FOXO3a nuclear translocation, stimulates motor neuron death 
(Milligan, Prevette et al. 1995; Dolcet, Egea et al. 1999; Soler, Dolcet et al. 1999; Garces, 
Haase et al. 2000).  In addition, the EC50 for cell death in dissociated cultures of spinal 
cord were 300 times higher than those necessary to trigger the death of 50% of the motor 
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neurons in pure cultures (Table 1), which can explain the absence of protective effect and 
the corroboration of the results using similar cultures (Barthelemy, Henderson et al. 
2004).  
In summary, the results reveal that Hsp90 inactivation of the purine P2X7 receptor is 
critical to prevent motor neuron apoptosis induced by activation of PTEN followed by 
inactivation of the Akt, dephosphorylation of FOXO3a and expression of Fas ligand.    
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CHAPTER 3: MUTANT SOD FACILITATES HSP90 NITRATION 
Introduction 
Mutations in the superoxide dismutase gene are associated with the development of 
Amyotrophic Lateral Sclerosis (ALS) (Deng, Hentati et al. 1993; Rosen, Siddique et al. 
1993; Gurney, Pu et al. 1994; Wong, Pardo et al. 1995; Bruijn, Beal et al. 1997; Bruijn LI 
1997; Martin, Price et al. 2000; Wong, Cai et al. 2002; Wang, Sharma et al. 2008; Wang, 
Deng et al. 2009).  Under normal conditions, SOD converts superoxide to hydrogen 
peroxide and oxygen preventing oxidative stress (McCord and Fridovich 1969).  
However, mutant SOD induces neurodegeneration by an unknown and highly 
controversial toxic gain of function (Reaume, Elliott et al. 1996; Bruijn, Houseweart et al. 
1998).  Wild type SOD contains zinc and copper, which is responsible for enzyme 
stability and catalytic function.  Mutant forms of SOD have reduced zinc affinity yet still 
retain copper (Lyons, Liu et al. 1996) suggesting a role for copper in the disease state. 
Immunohistochemistry of spinal cords from mutant SOD transgenic animals show 
intense nitrotyrosine immunoreactivity (Ferrante, Shinobu et al. 1997), a posttranslational 
modification associated with the production of reactive nitrogen species such as 
peroxynitrite.  However transgenic animals expressing a SOD in which the residues that 
coordinate the copper were mutated (Quad SOD), still develop disease but with a slower 
progression (Subramaniam, Lyons et al. 2002).  Extensive biochemical analysis of the 
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quad mutant SOD catalytic activity has yet to be performed.  Consequently, the role of 
copper in the development of mutant SOD related toxicity is highly controversial.   
Peroxynitrite is a powerful oxidant associated with the nitration of protein tyrosine 
residues.  Peroxynitrite is formed by the diffusion limiting reaction between superoxide 
and nitric oxide (Beckman, Beckman et al. 1990; Padmaja and Huie 1993; Beckman and 
Koppenol 1996; Spear, Estévez et al. 1997; Nauser and Koppenol 2002).  Nitration of 
Hsp90 by peroxynitrite has been shown to induce motor neuron cell death by a Fas 
dependent mechanism (Franco, Ye et al. 2013).  Nitrated Hsp90 is present in a variety of 
neurological pathologies including spinal cord injury and ALS (Franco, Ye et al. 2013).  
However it remains unknown whether there is a link between SOD mutations and Hsp90 
nitration in ALS. 
More than 20 years after the original reports linking mutations on the gene of the SOD 
and ALS, the mechanism mutant SOD toxicity and the contribution of copper to the 
development of ALS remain unknown and highly controversial.  Here we investigated 
the hypothesis that mutant SOD facilitates Hsp90 nitration, which in turn stimulates 
motor neuron death.  Nitrated Hsp90 immunoreactivity was found in spinal cord motor 
neurons from patients and the G93A transgenic mouse model of ALS. Nitrated Hsp90 
was present only in motor neurons at symptom onset and levels increase as disease 
progresses in the transgenic mouse model.  Zinc deficient SOD and quad mutant SOD 
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bound Hsp90 and selectively facilitated the nitration of Hsp90.  These results suggest that 
mutant SOD facilitate Hsp90 nitration within motor neurons. 
Materials and Methods 
Animal procedures:  All procedures using laboratory animals were performed in 
accordance with the Guide for the Care and Use of Laboratory Animals of the National 
Institutes of Health. Male hemizygous NTac:SD-TgN(SOD1
G93A
)L26H rats (Taconic), 
were bred crossing with wild-type Sprague-Dawley female rats. Rats were housed with a 
12-h light-dark cycle with ad libitum access to food and water. Symptomatic disease 
onset was determined by periodic clinical examination for abnormal gait, typically 
expressed as subtle limping or dragging of one hind limb. Rats were euthanized when 
reached disease end stage. All surgery was performed under 90% ketamine – 10% 
xylazine anesthesia, and suffering, discomfort or stress was minimized.  
Histology:  Animals were deeply anesthetized and transcardial perfusion was performed 
with 0.9% saline and 4% paraformaldehyde in 0.1 M PBS (pH 7.2–7.4) at a constant flow 
(1 mL/min). Fixed spinal cord was removed, post-fixed by immersion for 24 h, and then 
transverse sectioned serially (30–40 μm) on a vibrating microtome. Serial sections were 
collected in 100 mM PBS for immunohistochemistry. Free-floating sections were 
permeabilized for 30 min at room temperature with 0.3% Triton X-100 in PBS and 
passed through washing buffered solutions.  Sections were blocked with 5% BSA:PBS 
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for 1 hour at room temperature, and incubated at 4 °C overnight with primary antibodies 
in 0.3% Triton X-100 and PBS [rabbit anti-Hsp90 (1:100, Santa Cruz Biotechnology), 
mouse-anti Hsp90 (1:200, Abcam)  mouse anti-nitrated Hsp90 (1:200, Franco 2013), 
rabbit anti-GFAP (1:500, Sigma), rabbit anti-ChAT (1:300, Millipore), rabbit anti-
humanSOD1 (1:500), and mouse anti-NO2Tyr (1:200, (Franco, Ye et al. 2013))].  
Immunoreactivity of nitrotyrosine was completely blocked by pre-incubation of the 
primary antibody with free nitrotyrosine (10 mM). After washing, sections were 
incubated in 1:1,000-diluted secondary antibodies conjugated to Alexa Fluor 488 and/or 
Alexa Fluor 633 (Invitrogen). Antibodies were detected by confocal microscopy using a 
confocal Olympus FV300 microscope. 
Motor neuron isolation:  Motor neurons were prepared as previously described 
(Henderson, Bloch-Gallego et al. 1995; Estevez, Spear et al. 1998; Raoul, Henderson et 
al. 1999).  Motor neurons were plated on 96 well plates (1,000 cells per well), 4 well 
plates (2,000 cells per well), 8 well chamber (10,000 cells/well) or 4 well chamber 
(20,000 cells/well) coated with poly-DL-ornithine and laminin (Sigma).  Motor neurons 
were maintained in motor neuron media [B27, heat inactivated horse serum, glutamine, 
glutamate, 3-mercaptoethanol (all from Gibco – Invitrogen, Carlsbad, CA) and trophic 
factors (1 ng/ml BDNF, 0.1 ng/ml GDNF, 10 ng/ml cardiotrophin-1) in neurobasal], and 
incubated in a 5% CO2 humidified atmosphere at 37°C. 
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SOD delivery:  SOD was delivered to motor neurons in suspension or after three days in 
culture.  Recombinant protein was delivered as previously described [(Estévez, Crow et 
al. 1999), 1/265 dilution of chariot]. 
Immunoflourescence:  Immunofluorescence was performed as previously described 
(Estevez, Spear et al. 1998).  Cells were incubated with signal enhancer (Invitrogen) for 
30 minutes before blocking.  Primary antibodies for NO2Hsp90, NO2Tyr, and Hsp90 
were incubated in blocking solution in a humidified chamber at 4C overnight.  
Secondary AlexaFluor antibodies were incubated for 1 hour at room temperature, before 
staining with DAPI and mounting using ProLong Gold (Molecular Probes, Invitrogen, 
Eugene, OR). 
Nitration assay:  Recombinant protein (1 mg/mL in PBS) was added to brain homogenate 
(1 mg/ml in PBS) before the addition of peroxynitrite (0.5 mM) while vortexing.  
Samples were then diluted in lamelli buffer and processed as described previously 
(Franco, Ye et al. 2013).  Western blots were performed using primary antibodies against 
NO2Hsp90 (1/1,000, mouse), Hsp90 (1/1,000 rabbit), NO2tyrosine (1/2,000, rabbit) and 
GAPDH (1/50,000, mouse).  Secondary antibodies were obtained from Licor (1/25,000, 
anti-mouse and anti-rabbit). 
Western blot analysis of tissue: For spinal cord protein extraction, spinal cords were 
completely dissected and embedded in lysis buffer [50 mM Hepes (pH 7.5), 50 mM 
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NaCl, 1% Triton X-100, and complete protease inhibitor cocktail (Sigma)] and sonicated 
six times for 3 s. Protein concentration was measured with Bicinchoninic Acid (BCA) kit 
(Sigma). Protein extracts were diluted in loading buffer (15% SDS, 0.3 M Tris (pH 6.8), 
25% glycerol, 1.5 M β-mercaptoethanol, and 0.01% bromophenol blue).  Protein samples 
(40 μg) were resolved on 12% SDS-polyacrylamide gel and transferred to PVDF 
membrane (Amersham). Membranes were blocked for 1 h in Tris-buffered saline (TBS), 
0.1% Tween-20, and 5% non-fat dry milk, followed by overnight incubation with 
primary antibody [rabbit anti-Hsp90 (1:1,000, Santa Cruz), mouse anti-nitrated Hsp90 
and mouse anti-β-actin (1:4,000, Sigma)] diluted in the same buffer. The membrane was 
incubated with peroxidase-conjugated secondary antibodies, Goat anti-mouse-HRP and 
Goat anti-rabbit-HRP (1:5000, Thermo) for 1 h and washed and developed using the ECL 
chemiluminescent detection system (Thermo). NO2Hsp90 and Hsp90 (~90 kDa) bands 
were used to quantify the data. The intensities of all protein bands were normalized with 
the housekeeping gene, β-actin, using the ImageJ software. 
Results 
Nitrated Hsp90 was present in ALS patients.  We have previously shown that nitration 
Hsp90 at residues 33 and 56 is necessary and sufficient to stimulate motor neuron 
apoptosis (Franco, Ye et al. 2013).  Immunoreactivity for Hsp90 nitrated in tyrosine 56 
(Ye, Quijano et al. 2007; Franco, Ye et al. 2013) was present in the spinal motor neurons 
from postmortem tissue of ALS patients, but could not be detected in the spinal cord of 
 30 
age matched controls (Fig. 10).  The immunoreactivity was prominent in motor neurons 
and could not de detected in other cell type.  These results suggest that nitrated Hsp90 is 
present in spinal cord motor neurons of ALS patients before the cells die.  These results 
suggest that nitrated Hsp90 can cause motor neuron degeneration in ALS.   
Nitrated Hsp90 immunoreactivity was detected in motor neurons from symptom onset 
and increased with disease progression in the G93A mouse model of ALS.  The time 
course of Hsp90 nitration in the spinal cord of G95A transgenic mouse model of ALS 
was determined to correlate the presence of nitrated Hsp90 with disease onset and 
progression.   Nitrated Hsp90 was detected in ventral motor neurons during early 
symptomatic (90 days) and symptomatic stages (120 days) of the disease but not in 
presymtomatic (60 days), nontransgenic or mice transgenic for wild type SOD (Fig. 
11A). The increase in glial fibrillary acidic protein (GFAP) immunoreactivity correlated 
with disease progression as previously reported (Schiffer, Cordera et al. 1996; Hall, 
Oostveen et al. 1998; Jaarsma, Teuling et al. 2008).   Western blotting analysis of ventral 
spinal cord from transgenic mouse reveal significant increase in nitrated Hsp90 in 
symptomatic mice in comparison to nontransgenic animals, without changes in total 
Hsp90 (Fig. 11B).  The results suggest that nitrated Hsp90 immunostaining represents an 
increase in the oxidative modification of Hsp90 rather than an increase in the amount of 
chaperone.    
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In addition, the GFAP and nitrated Hsp90 co-localize only in the late symptomatic phase, 
when significant motor neuron death already occurred (Fig. 11A).  The presence of 
nitrated Hsp90 in astrocytes during the end stage of the disease could be due to nitration 
of astrocytic Hsp90 or to astrocyte phagocytosis of the motor neuron nitrated chaperone.  
To determine whether Hsp90 could be nitrated in the astrocyte, purified cortical and 
spinal astrocyte cultures were treated with peroxynitrite.  Nitrated Hsp90 was not 
detected in cultured astrocytes 1 min or 24 hour after 5 min incubation with 1 mM 
peroxynitrite (Fig. 11C).  Nitrated Hsp90 was in astrocyte homogenate incubated with 
peroxynitrite at the same concentration (Fig. 11C), suggesting that in astrocytes Hsp90 is 
protected from nitration.  In aggregate, the results reveal that Hsp90 is nitrated in motor 
neurons during the symptomatic phase of ALS, which can explain symptom onset in 
ALS. 
Mutant SOD increases protein nitration in vitro.  Mutant SOD has reduced affinity to 
bind zinc, which is associated with increased protein nitration (Ischiropoulos, Zhu et al. 
1992; Beckman, Carson et al. 1993; Crow, Strong et al. 1997).   The role of zinc deficient 
SOD on nitration of Hsp90 was investigated by incubating nontransgenic spinal cord 
homogenate with peroxynitrite in the presence of zinc deficient SOD or wild type SOD.  
The nitrated homogenates were analyzed for nitrotyrosine and nitrated Hsp90.  The 
addition of BSA was added to control for the effect of peroxynitrite alone on nitration of 
proteins.  Zn deficient SOD produced an 8 fold increase in nitration as compared with the 
control or wild type SOD (Fig. 12A).  These results corroborated previous reports 
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showing that zinc deficient SOD enhances peroxynitrite-mediated nitration (Crow, Strong 
et al. 1997).  However, the relevance of copper in SOD toxicity is highly controversial.  
Transgenic animals for a SOD where the copper binding site has been deleted (Quad 
mutant) develop motor neuron disease (Wang, Slunt et al. 2003).  This suggests that 
copper may not be required for mutant SOD toxicity.  The presence of oxidative stress in 
this transgenic model animal was not tested.  Incubation of spinal cord homogenates with 
peroxynitrite in the presence of quad mutant SOD increased protein nitration to levels 
comparable to Zn deficient SOD.   
When the same samples were analyzed for nitrated Hsp90, both zinc and quad mutant 
SOD increased the levels of nitrated Hsp90 by 79 and 13 fold, which represents an 
increase of 10 and two fold respect to total nitration. In addition, wild type SOD had no 
effect on Hsp90 nitration (Fig. 12B).  These results reveal that mutant SOD selectively 
enhances Hsp90 nitration by peroxynitrite.   
Surface plasmon resonance was used to characterize the kinetics of the interactions of 
Hsp90 and SOD.  Both Zn deficient, quad mutant SOD and APO C111S bound Hsp90, in 
contrast, no binding of fully metallated wild type SOD to Hsp90 was detected (Table 2).  
These findings suggest that Hsp90 bind partially and unmetallated SOD, which 
selectively increases the nitration of the chaperone. 
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Mutant SOD induce motor neuron cell death requires copper and peroxynitrite 
formation.  The nitration of Hsp90 in the presence of quad mutant SOD suggests that this 
enzyme facilitate Hsp90 nitration because it has redox properties or due to a 
conformation change in the chaperone.  To determine if quad mutant SOD induced motor 
neuron death in culture, recombinant protein was intracellularly delivered to motor 
neurons using the cell permeant agent, Chariot.  Delivery of zinc deficient and quad 
mutant SOD stimulates motor neuron death (Fig. 13A).  Similar treatment with copper 
deficient SOD did not affected motor neuron survival (Fig. 13A).  The copper chelator, 
bathocuproine, prevented cell death induced by both zinc deficient and quad mutant SOD 
suggesting copper is required for the induction of cell death (Fig. 13B).   
The delivery of both zinc deficient or quad mutant SOD to motor neurons resulted in 
increased immunoreactivity for nitrated Hsp90 (Fig. 13C).  Protein nitration requires 
nitric oxide and peroxynitrite formation (Estevez, Spear et al. 1998; Estévez, Crow et al. 
1999; Estevez, Sampson et al. 2000) therefore, the effect of nitric oxide synthase 
inhibitors on motor neuron survival was investigated.  The nNOS inhibitor, L-NAME, 
prevented mutant SOD mediated motor neuron cell death indicating that production of 
nitric oxide is required for the induction of death (Fig. 13D).  The superoxide dismutase 
mimetic, MnTBAP, and superoxide and peroxynitrite scavenger, FeTCCP, also prevented 
motor neuron death stimulated by Zn deficient and Q mutant SOD (Fig. 13D).  These 
results suggest the zinc deficient and quad mutant SOD induce motor neuron death by a 
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similar copper dependent mechanism involving peroxynitrite formation and nitration of 
Hsp90. 
The in vitro results suggest that the spinal cord of transgenic mice for the Q SOD should 
have nitrotyrosine.  Indeed, the spinal cord of the mice transgenic for the quad mutant 
SOD showed intense immunoreactivity for nitrotyrosine (Fig. 14).   However, the 
nitrotyrosine immunoreactivity was not as intense as that of aged matched transgenic 
animals for the G93A SOD mutation suggesting the rate of nitration is slower in the quad 
mutant animal (Fig. 14).  These observations are in agreement with a slower development 
and progression of the disease in the quad mutant.   
Discussion 
Metal deficient SOD has reduced stability leading to protein unfolding (Rakhit, Crow et 
al. 2004; Rumfeldt, Lepock et al. 2009; Sahawneh, Ricart et al. 2010).  The absence of 
nitrated Hsp90 in wild type samples suggests that SOD protein unfolding may increase 
Hsp90 susceptibility to nitration.  Chaperone such as Hsp90 bind unfolded protein to 
prevent degradation and facilitate refolding.  
The presence of nitrotyrosine in the spinal cord of ALS patients and animal models of the 
disease is well established (Abe, Pan et al. 1995; Beal, Ferrante et al. 1997; Ferrante, 
Shinobu et al. 1997; Duda, Giasson et al. 2000).  However, the role that nitrotyrosine and 
oxidative stress play in the pathology of the disease is still highly controversial.  Our 
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results reveal that the zinc deficient and quad mutant SOD induce motor neuron death by 
a similar copper dependent mechanism involving peroxynitrite formation and nitration of 
Hsp90 (Fig. 13A-D).  We have previously shown that nitration of Hsp90 in tyrosine 33 or 
56 is necessary and sufficient to make the chaperone toxic (Franco, Ye et al. 2013).  We 
develop a monoclonal antibody against Hsp90 nitrated in tyrosine 56, which was fully 
characterized for specificity (Ye, Quijano et al. 2007; Franco, Ye et al. 2013).  Using this 
antibody, we found that Hsp90 nitration occurs during the symptomatic phase of ALS 
and is found only within the motor neurons (Fig. 10).  Nitrated Hsp90 immunoreactivity 
appears at symptom onset and coincides with motor neuron death.  
Nitrated Hsp90 immunoreactivity was restricted to motor neurons in postmorterm spinal 
cord samples from ALS patients (Fig. 10) and in early stages of the disease in the spinal 
cord of the G93A mouse models of the disease (Fig. 11A and B).  The inability of 
peroxynitrite to nitrate Hsp90 in cultured astrocytes (Fig. 11C) suggests that Hsp90 is 
protected from nitration in these cells.  These results also suggest that nitrated Hsp90 in 
astrocytes at end stages of the disease is likely due to the removal of motor neuron debris 
by astrocytes rather than nitration of the astrocyte Hsp90.  The specific formation of 
nitrated Hsp90 in motor neurons may explains how glial cell specific knockdown of 
mutant SOD has no effect on disease onset and why neuron specific expression of mutant 
SOD is enough to produce disease (Boillee, Yamanaka et al. 2006; Jaarsma, Teuling et al. 
2008; Yamanaka, Chun et al. 2008).   
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Peroxynitrite nitration can by catalyzed by SOD and the catalysis is enhanced in zinc 
deficient SOD (Ischiropoulos, Zhu et al. 1992; Crow, Sampson et al. 1997; Adams, 
Franco et al. 2015).  Although original reports on the Q mutant showed that the enzyme 
has no superoxide dismutase activity, the metal content of the enzyme or other redox 
properties were not investigated (Wang, Slunt et al. 2003).  Our result show enhanced 
tyrosine nitration by peroxynitrite in the presence of quad mutant, suggesting that the 
protein possess redox activity. In fact the increase in nitration was similar to the nitration 
catalyzed by Zn-deficient SOD (Fig. 12A). Furthermore, motor neuron death stimulated 
by Q mutant, and Zn-deficient SOD were prevented by inhibition of nitric oxide 
production, and scavenging of superoxide and peroxynitrite (Fig. 13D). This provides 
further support for a redox mechanism mediated by Q SOD in the pathogenesis of the 
transgenic mouse.   In addition, quad mutant SOD induced motor neuron death in culture 
was preceded by the nitration of Hsp90.  In fact, both Zn-deficient and Q mutant 
selectively facilitated the nitration of Hsp90 (Fig. 13C).  The enhanced nitration could be 
caused by increase catalysis, but it can also be caused by changing the conformation of 
Hsp90 to become more favorable to nitration.  Metal deficient SOD has reduced stability 
leading to protein unfolding (Rakhit, Crow et al. 2004; Rumfeldt, Lepock et al. 2009; 
Sahawneh, Ricart et al. 2010).  The absence of nitrated Hsp90 in wild type samples 
suggests that SOD protein unfolding may increase Hsp90 susceptibility to nitration.  
However, wild type SOD did not bind Hsp90 (table 2), suggesting that the interaction 
with Hsp90 may be due to the unfolding of SOD, or a specific SOD conformation 
provided by partially metillated proteins.  ALS linked mutations in SOD have been 
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shown to have a reduced zinc affinity (Lyons, Liu et al. 1996; Crow, Sampson et al. 
1997) that leads to destabilization of the dimer and protein unfolding (Rumfeldt, Lepock 
et al. 2009; Sahawneh, Ricart et al. 2010). As a consequence, there is increased 
aggregation of the mutant SOD monomers (Rakhit, Crow et al. 2004; Rumfeldt, 
Stathopulos et al. 2006; Rumfeldt, Lepock et al. 2009).  These mutants favor a zinc 
deficient monomer, where copper remains bound (Rumfeldt, Lepock et al. 2009; 
Sahawneh, Ricart et al. 2010).  Mutant SOD unfolding leads to the interaction with 
chaperones such as Hsp70 (Shinder 2001).  Interestingly, the degree of instability of the 
APO state of SOD correlates to length of survival (Sato 2005) and this relationship may 
be due Hsp90 binding to mutant SOD and subsequent nitration.  The direct interactions of 
mutant SOD to heat shock chaperones such as Hsp70 and Hsp90 may facilitate nitration.  
However, only Hsp90 is responsible for induction of motor neuron death (Franco, Ye et 
al. 2013).  Nitrated Hsp90 stimulates motor neuron death by a P2X7 receptor/Fas 
dependent pathway that is consistent with a downstream effector of mutant SOD 
stimulated motor neuron death (Raoul, Estévez et al. 2002).  
Our results demonstrate that quad mutant SOD toxicity is dependent on copper (Fig. 
13B). These results are contrary to previous findings where transgenic mutant SOD 
animals crossbred with animals containing a genetic deletion of the copper chaperone for 
SOD (CCS) still developed motor neuron disease (Subramaniam, Lyons et al. 2002).  
These animals had a 90% reduction of copper incorporation into mutant SOD, however 
the remaining copper containing SOD may be enough for the animal to develop the 
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disease (Beckman, Estévez et al. 2001).  The dependency of the quad mutant SOD to 
bind copper suggests the presence of an alternative binding site.  Since this site is a 
secondary binding site it is possible that the copper binding changes the enzyme’s 
confirmation reducing its ability to facilitate protein nitration leading to slower disease 
progression.  Many of the argument against the role of redox properties of SOD playing a 
role in the pathogenesis of ALS come from genetic studies in which the biochemistry of 
the enzyme was not investigated at all or poorly characterized.  The presence of markers 
of oxidative damage such as nitrotyrosine in all animal models of the disease and post 
mortem samples of ALS patients coupled with a number of studies showing how these 
markers stimulate motor neuron death, provide the best rounded hypothesis for ALS 
pathogenesis.  The presence of nitrated Hsp90 in motor neurons of both animal models 
and human patients provide the first complete pathway explaining ALS pathology. 
Our findings demonstrate that mutant SOD facilitates Hsp90 nitration in motor neurons in 
a copper and peroxynitrite dependent mechanism.  Hsp90 nitration occurs at disease 
onset and increases during disease progression in a G93A transgenic animal.  In contrast, 
astrocytes are not nitrated during disease onset nor do they become nitrated in vivo.  
These results suggest that mutant SOD induce cell autonomous neuronal cell death 
through nitrated Hsp90. 
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CHAPTER 4: CHRONIC INHIBITORY EFFECT OF RILUZOLE ON 
TROPHIC FACTOR PRODUCTION
1
 
Introduction 
Amyotrophic lateral sclerosis (ALS) is a devastating and incurable neurological disease, 
characterized by the degeneration of pyramidal neurons in the motor cortex and motor 
neurons in the brain stem and spinal cord.  ALS patients live without medical 
intervention an average of one to five years following diagnosis.  Riluzole is the only 
drug that shows a small but consistent protective effect both in patients and transgenic 
mice models of ALS (Bensimon, Lacomblez et al. 1994; Gurney, Cutting et al. 1996; 
Lacomblez, Bensimon et al. 1996; Lacomblez, Bensimon et al. 1996; Gurney, Fleck et al. 
1998; Orrell 2010; Miller, Mitchell et al. 2012).  Riluzole has been shown to block 
sodium channels, activate G-proteins and reduce glutamate toxicity (Doble 1997; 
Meininger, Lacomblez et al. 2000; Cheah, Vucic et al. 2010; Bellingham 2011).  
However, the primary mechanism by which riluzole exerts its protective effects in ALS 
remains unknown.  
 Astrocytes and other glial cells produce trophic factors that support motor neuron 
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survival (Schnaar and Schaffner 1981; Eagleson, Raju et al. 1985; Eagleson and Bennett 
1986; Ang, Bhaumick et al. 1993; Arce, Pollock et al. 1998). Riluzole enhances the 
astrocytic production of these factors in cell culture (Peluffo, Estévez et al. 1997).   The 
incubation of cortical astrocytes with riluzole stimulates the production of brain derived 
neurotrophic factor (BDNF), glia derived neurotrophic factor (GDNF) and nerve growth 
factor (NGF) (Mizuta, Ohta et al. 2001).  Schwann cells also produce trophic factors that 
promote axon regeneration following exercise and nerve injury (Wilhelm, Xu et al. 2012; 
Xu, Rosen et al. 2013).  Cardiotrophin-1 (CT-1) is a potent motor neuron trophic factor 
that prevents motor neuron death after axotomy and delays death in animal models of 
ALS produced by muscle (Pennica, Arce et al. 1996; Bordet, Lesbordes et al. 2001).  
Initial studies on the effect of riluzole lead us and others to postulate that riluzole may 
exert at least in part its protective effects on motor neurons indirectly, by promoting 
trophic factor production by astrocytes and other glial cells (Peluffo, Estévez et al. 1997; 
Mizuta, Ohta et al. 2001).  Here we investigated the effects of short and long time 
incubation with riluzole on trophic factor production by Schwann cells and astrocytes. 
Both cell types play an important role in cellular maintenance of motor neurons.  We 
investigated also concentrations of trophic factors produced in brain, spinal cord, and 
sciatic nerve of C57BL/6J mice at different time points after continuous or discontinuous 
riluzole administration and correlated the in vivo results to specific glial cell responses.  
Our findings provide new insights on the potential mechanism of action of riluzole as a 
therapeutic treatment for ALS and possibly spinal cord injury. 
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Materials and Methods 
Astrocyte cell culture:  Spinal cords from one to three days old Sprague Dawley rats were 
used to prepare astrocytes as described previously (Saneto and Vellis 1987; Peluffo, 
Estévez et al. 1997). Once confluent (approximately 5-8 days), cells were shaken at 300 
RPM for 2 days then treated with 10 μM arabinose C.  Following a couple days recovery, 
cells were split and seeded on a 60mm dish at a density of one million cells or half a 
million for a 35mm dish.  Cells were maintained in culture for no more than 22 days. 
Motor neuron cell culture:  Rat embryo motor neurons were purified using 6% OPTI 
prep and further purified using immunoaffinity.  Cells were cultured in neurobasal 
medium containing glutamine, glutamate, β-mercaptoethanol, and B27 supplement 
(Gibco-Invitrogen) as previously described (Estevez, Spear et al. 1998; Pettmann and 
Henderson 1998; Raoul, Henderson et al. 1999) in the presence or absence of brain-
derived neurotrophic factor (BDNF, 1 ng/mL), glial-derived neurotrophic factor (GDNF, 
0.1 ng/mL), and cardiotrophin 1 (CT-1, 10 ng/mL).  Motor neuron survival was 
determined by counting by hand in four well plates (Nunc) or by calcein staining 
(Molecular Probes, Invitrogen) according to manufacturer’s instruction.  Extracellular 
calcein was quenched with 100 µg/mL hemoglobin and the images were captured using 
the RUNNER (Trophos, Marseilles, France).  Data was analyzed using Tina software 
(Trophos). 
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Schwann Cell culture:  Primary Schwann cells were isolated from the sciatic nerves of 
newborn Sprague Dawley rats with modifications as previously described (Brockes, 
Fields et al. 1979; Thaxton, Bott et al. 2011).  250,000 cells (35 mm dish) or 500,000 
cells (60 mm dish) were grown in D10M (10% FBS, 20 μg/ml pituitary extracts and 2μM 
forskolin in DMEM) on poly-L-lysine coated plates (200 μg/mL) until confluency. Media 
was changed three days before the experiment was started.  Experiments were conducted 
on Schwann cells that were passaged no more than four times.   
Conditioned Media:  Astrocytes or Schwann cells were treated with 1 µM riluzole for 
indicated time period.  For chronic treatments, media was changed with fresh riluzole 
every 2-3 days.  Media was removed and cells were washed with DPBS prior to addition 
of conditioning media (L15 supplemented with sodium bicarbonate (22 mM), 
conalbumin (0.1 mg/ml), putrescine (0.1 mM), insulin (5 µg/ml), and sodium selenite (31 
nM). Astrocytes or Schwann cells conditioned this media for 24 hours prior to collection.  
Conditioned media was further diluted in motor neuron media prior to plating motor 
neurons.  Motor neurons were cultured in the presence of conditioned media for three 
days then counted. 
PCR Analysis:  RNA was extracted from Schwann cells plated on a 35 mm dish using 
Trizol.  1 μg RNA was used to synthesize cDNA using Superscript III (Invitrogen) 
according to manufacturer’s instruction.  2 μl of cDNA product was used as template for 
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qPCR analysis.  CT-1, BDNF, and GDNF levels were measured using Taq Man probes 
and master mix according to manufacturer’s instruction. 
Animal Studies:  Male C57BL/6J mice were given riluzole treated water (100 μg/ml) for 
given time points.  Water was replaced with freshly prepared riluzole every 2-3 days.  
Brain, spinal cord, and sciatic nerve were removed for subsequent analysis.  Untreated 
mice were sacrificed for control. 
ELISA:  Brain, spinal cord, and sciatic nerve were homogenized in PBS containing 
PMSF, and protease inhibitor cocktail.  Samples were diluted to a concentration of 175 
μg/mL and analyzed using ELISA [CT-1 (R & D Systems), BDNF and GDNF 
(Abnova)].  ELISA was performed according to manufacturer’s instructions. 
Results 
Riluzole treatment stimulates glial cells to produce CT-1.  Riluzole stimulates trophic 
factor production by astrocytes (Peluffo, Estévez et al. 1997; Mizuta, Ohta et al. 2001).  
Incubation of motor neurons with media that was previously conditioned by astrocytes in 
the presence of 1-10 μM riluzole significantly increases motor neuron survival when 
compared to cells cultured in conditioned media from untreated astrocytes (Peluffo, 
Estévez et al. 1997).  Since the trophic factors BDNF, GDNF and CT-1 are critical to 
motor neuron survival, we investigated the effect of riluzole on production of these 
trophic factors by astrocytes using conditions previously described (Peluffo, Estévez et 
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al. 1997).  There was a small, but statistically significant change in CT-1 mRNA levels 
with no change in mRNA levels of BDNF, and GDNF of riluzole treated astrocytes when 
compared to untreated controls (Fig. 15A).  Since mRNA levels do not reflect protein 
levels, neutralizing antibodies to BDNF, GDNF and CT-1 were used to determine the 
effect of each trophic factor present in conditioned media on motor neuron survival. 
Motor neurons were cultured in the absence of trophic factors and survival was assessed 
after 24 h in culture. Incubation of motor neurons with media that was previously 
conditioned by astrocytes for 24 h partially protected motor neurons from trophic factor 
deprivation-induced cell death (Fig. 15B). This protection was significantly increased by 
conditioned media from astrocytes that were incubated in the presence of riluzole for 24 h 
prior to media conditioning (Fig. 15B). Antibodies against CT-1 had no effect on motor 
neuron survival in the presence of conditioned media from untreated astrocytes, but 
blocked the additional protection afforded by the media from riluzole-treated astrocytes 
(Fig. 15A), suggesting that CT-1 production is stimulated by riluzole. As expected, 
addition of antibodies against GDNF or BDNF also reversed the protection provided by 
riluzole treated astrocyte conditioned media (Fig. 15B) since these factors are basally 
secreted by astrocytes (Schaar, Sieber et al. 1993; Dougherty, Dreyfus et al. 2000; Jean, 
Lercher et al. 2008; Fulmer, VonDran et al. 2014). These results imply that in addition to 
stimulate the production of BDNF and GDNF by cortical astrocytes (Mizuta, Ohta et al. 
2001), riluzole also induces the synthesis and release of CT-1 by spinal astrocytes.  
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Schwann cells provide trophic factor support for motor neurons under stress conditions 
(Wilhelm, Xu et al. 2012; Xu, Rosen et al. 2013).  Therefore we investigated if riluzole 
could also stimulate trophic factor production in these cells at the same concentrations of 
drug used for astrocytes. Initial experiments were conducted to determine the dilution of 
riluzole-treated and untreated Schwann cell conditioned media that would provide 
discernable differences in trophic factor support.  Due to a higher level of trophic support 
in Schwann cell conditioned media, a 1:25 dilution was selected to perform subsequent 
experiments compare to the 1:10 dilution applied to conditioned media from astrocytes 
(Sup. Fig. 1A). Incubation of Schwann cells with riluzole for 24 h prior to conditioning 
the media significantly increased the protection provided to motor neurons in comparison 
to media from untreated cells (Fig. 15C). Neutralizing antibodies against CT-1 
completely abolished the protection afforded by conditioned media from riluzole-treated 
Schwann cells (Fig. 15C).  In the same conditions, neutralizing antibodies against BDNF 
and GDNF had no effect on motor neuron survival (Sup. Fig. 1B).  In contrast, 
neutralizing antibodies against GDNF but not BDNF, reduced motor neuron survival in 
untreated conditioned media (Sup. Fig. 1B).  In agreement with these observations, the 
levels of CT-1 messenger RNA were significantly increased after 24 h incubation with 
riluzole, while no changes were detected for GDNF and BDNF messenger RNAs (Fig. 
15D).  These results reveal that Schwann cells in culture produce CT-1 and that the 
production and release of CT-1 is enhanced by riluzole.  Incubation of astrocytes and 
Schwann cells with riluzole had no effect on cellular morphology or number (Sup. Fig. 
1A and B). Together, these results show that riluzole treatment increases trophic factor 
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deprived-motor neuron survival by inducing release of CT-1 by both astrocytes and 
Schwann cells. 
Chronic riluzole treatment decreases trophic factor production by glial cells:  Since 
incubation of astrocytes and Schwann cells with riluzole for 24 h showed an increase in 
trophic factor production, we investigated whether longer incubation periods would 
results on higher and more stable production of trophic factors by glial cells.  
Surprisingly, incubation of astrocytes with riluzole for up to 6 days prior to media 
conditioning resulted in a significant reduction of the protection provided to motor 
neurons when compared with conditioned media from astrocyte cultures incubated with 
riluzole for 24 h (Fig. 16A).  To determine if the loss of the astrocytes response to 
riluzole was the result of the chronic incubation with riluzole or astrocyte senescence, 
parallel astrocyte cultures were maintained in the same conditions, but in the absence of 
riluzole.  These cultures were then treated with riluzole for 24 h prior to conditioning the 
media (5U1R, as described in Fig. 16A). Conditioned media from these cultures had a 
motor neuron trophic activity comparable to that of conditioned media from acute 
riluzole treated astrocyte (1R, Fig. 16A) and increases motor neuron survival above six 
days untreated astrocytes.  These results reveal that conditioned media derived from 
astrocytes after chronic incubation with riluzole had reduced trophic support.   
When the same experimental design was applied to Schwann cells, after 5 days in culture 
followed by 24 h incubation with riluzole the cells failed to respond to the drug (5U1R). 
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However, conditioned media from acute treatment (1R, Sup. Fig. 1C) was indeed 
protective. Quantitative RT-PCR showed a significant reduction in CT-1 levels after 3 
days of continuous incubation with riluzole while after 6 days in culture the cells became 
senescent. Therefore, conditioned media from Schwann cells incubated with riluzole for 
3 days was considered a long-term treatment with the drug. In agreement, this 
conditioned media showed reduced motor neuron trophic factor support (Fig. 16B), while 
the control riluzole treatment, 2 days in culture followed by 24 h incubation with the drug 
(2U1R, Fig. 16B) maintained motor neuron survival to levels comparable to acute 
riluzole incubation (1R, Fig. 16B) and increased motor neuron survival above 3 day 
untreated cells.  Long-term incubation of astrocytes and Schwann cell produced no 
change on the morphology or proliferation of the cells (Sup. Fig. 2A-C). These 
observations revealed that the long-term effects of riluzole were not due to loss of cell 
responsiveness to the drug.  In addition, the expression of CT-1 and BDNF messenger 
RNA in Schwann cells was decreased after long-term incubation with riluzole compared 
with one-day incubation, with the expression of BDNF mRNA lower than untreated 
control (Fig. 16D).  In astrocytes, long-term incubation with riluzole decreased 
expression of CT-1 compared with cultures treated for one day with the drug. 
Interestingly, BDNF and GDNF, but not CT-1 mRNA expression was below untreated 
control in astrocytes after 6 days riluzole incubation (Fig. 16C). These results suggest that 
the effect of riluzole on the regulation of trophic factors mRNA expression is trophic 
factor and cell type specific. Together these findings suggest that chronic exposure to 
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riluzole significantly reduces trophic factor production by glial cells, abolishing the 
protective effect observed on trophic factor deprived-motor neurons.   
Acute and chronic riluzole treatment has opposite effects on trophic factor production in 
vivo:  The effects of riluzole on trophic factor production were investigated in spinal 
cord, whole brain and sciatic nerve of C57BL/6J male mice after treatment with riluzole 
in the drinking water for various time periods.  In the spinal cord, riluzole significantly 
increased CT-1 levels after 15 days of continuous treatment.  However, the increase was 
only transitory since CT-1 production was reduced to basal levels after 30 days of 
treatment (Fig 17A).  In contrast, riluzole did not stimulate BDNF production at any time, 
but induced a significant decrease of BDNF levels after 30 days of treatment (Fig. 17A).  
GDNF production was significantly increased after 3 days of riluzole treatment and 
returned to basal levels after 6 days of continuous administration of the drug.  
Surprisingly, GDNF production decreased below control levels after 15 and 30 days of 
continuous treatment (Fig. 17A). These observations cannot be attributed to differences 
in drug intake since there were no changes in the water consumption by the mice 
throughout the study (6.5-7.5 ml/animal/day, independently of the treatment).  Thus, 
these findings are consistent with the repressive effects on BDNF, GDNF, and CT-1 
production observed in cell culture after long-term incubation of astrocytes with riluzole.   
In the sciatic nerve, treatment with riluzole increased CT-1 levels at 3 and 15 days.  
However, CT-1 levels were significantly decreased below control levels after 30 days of 
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continuous treatment with the drug (Fig. 17B).  Riluzole did not increase GDNF or 
BDNF concentration in the sciatic nerve but BDNF level was significantly decreased 
after 30 days of riluzole treatment. These findings are consistent with the repressive 
effects on BDNF and CT-1 production observed in Schwann cells following chronic 
treatment of riluzole in culture.  
In the brain, CT-1 levels increased only at 6 days, returning to basal levels at 15 and 30 
days of continuous riluzole administration.  Riluzole did not stimulate significant changes 
in GDNF concentration at any time, but increased BDNF concentrations in the brain after 
6 and 15 days treatment.  After 30 days of continuous riluzole administration, the BDNF 
concentration was reduced below control levels (Fig.  17C).  These results reveal that 
acute riluzole treatment activated the production of distinct combinations of CT-1, GDNF 
and BDNF in spinal cord, sciatic nerve and brain at different times.  However, the 
chronic treatment with riluzole led to a significant reduction of trophic factor production, 
in some cases below the control levels.   
Discontinuous riluzole treatment increases long-term CT-1 production in spinal cord:  
The opposite effects of the chronic and acute administration of riluzole in the animals 
lead us to investigate 1) whether the acute stimulatory effect could be maintained by 
discontinuous administration of the drug, and 2) whether the chronic inhibitory effect 
could be reversed.  As shown in Fig. 3, trophic factor levels were elevated between 3 and 
15 days then reduced by 15 or 30 days depending on the trophic factor and the tissue.  
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Based on these results, animals were continuously administered riluzole for 15 and 30 
days then riluzole was removed for 15 days. The treatment was then reinitiated for 
additional 6 or 15 days to avoid the chronic inhibitory effect (Fig. 18A).  Trophic factor 
levels were studied in spinal cord from treated animals. After the second period of 
riluzole administration, CT-1 concentration was significantly increased as compared to 
the untreated control independently of whether the drug was given for 15 or 30 days 
during the initial period (Fig. 18B). In the case of GDNF, continuous treatment with 
riluzole for 15 or 30 days decreased the trophic factors levels. This decrease could not be 
reverted by discontinuing the treatment for 15 days and treating with the drug for 
additional 6 or 15 days (Fig. 18C). Moreover, treatment of animals for 30 days with 15 
days resting period and 15 additional days with riluzole showed significantly more 
reduction in GDNF concentrations than animal continuously treated with riluzole for 30 
days (Fig. 18C). The concentration of BDNF was not increase respect to the control in 
any condition (Fig. 18D).  Similar to GDNF, BDNF levels in the spinal cord were 
significantly reduced after treatment of animals with riluzole for 30 days with a 15 days 
rest period than after 30 days of continuous administration (Fig. 18D). In combination, 
these observations suggest a complex regulation of the expression of trophic factors by 
riluzole. 
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Discussion 
Riluzole is the only FDA approved drug for the treatment of ALS.  However, the primary 
mechanism by which riluzole offers protection remains unknown.  In both spinal cord 
organotypic and enriched motor neuron cultures riluzole protects motor neurons from 
glutamate receptor hyperstimulation-induced death (Estevez, Stutzmann et al. 1995; 
Rothstein and Kuncl 1995).  These original observations are supported by new evidence 
of the anti-excitotoxic effect of the drug in ALS patients (Bellingham 2011; Cifra, 
Mazzone et al. 2013; Foerster, Pomper et al. 2013; Vucic, Lin et al. 2013).  However, 
these same reports conclude that the effects of riluzole on glutamate metabolism are not 
sufficient to explain its protective effects in ALS.  After the failure of the gabapentin 
clinical trial, riluzole was postulated to act on pathways other than the glutamatergic 
transmission (Meininger, Lacomblez et al. 2000). Riluzole stimulates trophic factor 
production by astrocytes (Peluffo, Estévez et al. 1997; Mizuta, Ohta et al. 2001).  
However, the effect of riluzole on trophic factor production in other cell types was not 
investigated.  Motor neuron survival is supported by trophic factors released by Schwann 
cells during development (Henderson, Phillips et al. 1994) and nerve regeneration (Xu, 
Rosen et al. 2013) but whether Schwann cells supported motor neuron survival in adult 
normal conditions remained unknown.  Here, we show for the first time that Schwann 
cells produce CT-1 in these conditions.  Although Schwann cell production of BDNF and 
GDNF contribute also to motor neurons survival in culture, CT-1 was the only factor 
induced in Schwann cells following riluzole treatment.  Results using conditioned media 
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from riluzole-treated Schwann cells support CT-1 as the major trophic factor induced by 
riluzole, since neutralizing antibodies against CT-1 reduced motor neuron survival to 
levels comparable to those of untreated conditioned media.  Similar findings were 
obtained with conditioned media from riluzole-treated astrocytes (Fig. 15). Previous 
reports shows that riluzole induces secretion of NGF, BDNF, and GDNF by cultured 
cortical astrocytes (Mizuta, Ohta et al. 2001). In contrast with these observations, acute 
incubation of spinal cord astrocytes with riluzole led to a significant increase in secretion 
of CT-1 but not BDNF or GDNF (Fig. 17).  However, in the brain of mice after acute 
treatment with riluzole, CT-1 and BDNF production was induced, without affecting 
GDNF levels.  These discrepancies between the cell culture and in vivo tissue effects may 
be due to direct or indirect effects of riluzole on other cell types. The difference in trophic 
factor production in the examined tissue suggests that responses to riluzole depend on the 
cell specific population within the corresponding tissue.  Surprisingly, long-term riluzole 
treatment of Schwann cells and astrocytes with riluzole resulted in a significant reduction 
of trophic activity (Fig. 16), suggesting a biphasic stimulatory-inhibitory effect of riluzole 
on the production of trophic factors.  
The regulation of the concentration of different trophic factors by oral administration of 
riluzole to mice was tissue and time dependent (Fig. 17).  While some trophic factors 
were initially increased over basal concentrations, all trophic factors concentrations 
dropped to basal levels and in some cases below basal levels after longer treatment with 
riluzole.   In agreement with the cell culture results, CT-1 was the only trophic factor 
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consistently induced after acute treatment of mice with riluzole in spinal cord, sciatic 
nerve and brain (Fig. 17).  BDNF and GDNF concentrations were initially increased in 
some tissues, but not others.  However, chronic treatment reversed to basal or below 
control levels for all three trophic factors (Fig. 17).  The half-life of riluzole in vivo is 
measured in hours.  In the nervous system, riluzole is removed at the level of the blood-
brain barrier by the P-glycoprotein (Milane, Fernandez et al. 2007; Milane, Vautier et al. 
2009; Milane, Fernandez et al. 2010; Dulin, Moore et al. 2013).  In patients and models 
of ALS both drug efflux transporters, P-glycoprotein and breast cancer-resistant protein 
(BCRP) are increased.  Gene deletion of P-glycoprotein or pharmacological inhibition of 
these transporters provides a small protective effect when riluzole is administer at disease 
onset in the G93A mouse model of ALS (Jablonski, Markandaiah et al. 2014).  This 
enhanced protection by riluzole is consistent with our observation of acute effects 
increasing trophic factor production.  However, decreased concentrations of riluzole in 
the nervous system could explain the return of the trophic factor concentrations to basal 
control levels, but not below those levels, suggesting there is a secondary inhibitory 
effect mediated by riluzole itself or by a metabolic product of riluzole that remains to be 
identified.   
Riluzole is undergoing clinical trials for the treatment of spinal cord injury and repair.  In 
order to maximize its therapeutic effects riluzole must be administered within hours of 
injury (Nogradi, Szabo et al. 2007). Thus, riluzole may be effective for treatment in 
spinal cord injury and repair in these conditions because trophic factor production by 
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astrocytes is induced locally at the critical time to prevent neuronal death and to facilitate 
axonal regeneration and growth (Li, Oppenheim et al. 1994; Bergerot, Shortland et al. 
2004).  These findings suggest that induction of the specific trophic factors in the right 
cells could be critical to achieve the desired beneficial therapeutic effect in spinal trauma. 
Most animal studies were conducted using continuous administration of riluzole for 2-3 
weeks (Nogradi and Vrbova 2001; Bergerot, Shortland et al. 2004; Nogradi, Szabo et al. 
2007; Dennys, Franco et al. 2014), which could result in a decreased of the potential 
beneficial effects.  However, it is also possible that the long-term treatment with riluzole 
induces an initial increase in trophic support, which helps axon regenerate through the 
affected area. Conversely, the chronic effect of riluzole could also be beneficial in this 
context, by decreasing the local production of trophic factors, which allows axons to 
leave the affected area to interact with the right targets.  
Trophic factors have shown to be protective in animal models of ALS.  However, the 
translation to clinical trials resulted in failure.  Most trophic factors investigated in 
clinical trials for ALS have been unsuccessful at extending patient survival (Group 1996) 
These trials used invasive delivery methods to ensure the trophic factor of interest would 
cross the blood brain barrier (Kastin, Akerstrom et al. 2003; Dennys, Franco et al. 2014).  
In summary, there are multiple factors that can explain trophic factors failure in clinical 
trails, including secondary effects due to systemic administration (Gould and Oppenheim 
2011).  The success of riluzole may be due to the stimulation of the local production of 
trophic factor by motor neuron associated cells.  However, independently of the 
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mechanism of riluzole action, here we show that riluzole regulates protein expression and 
it has opposite effects on the production of trophic factors.  Early stimulation of trophic 
factor production is followed by a decrease, in some cases below basal levels, which 
strongly suggest the second phase is not a consequence of loss of activity or habituation 
but inhibition of trophic factor production. Modifying the dosing regimen of riluzole may 
maximize the protective effects of the glial-derived trophic activity necessary to improve 
treatment of patients with ALS. We showed that discontinuous administration of riluzole 
maintained elevated CT-1 levels in the spinal cord in vivo (Fig. 18).  However, these 
same protocols of discontinuous riluzole treatment did not prevent down regulation of 
BDNF or GDNF.  In the case of GDNF, after 15 days treatment with riluzole with a 15 
days rest period, the concentrations of the trophic factor were not affected by further 
administration of the drug. In contrast, when the initial period of riluzole administration 
was 30 days, the additional treatment with riluzole further decreased the concentrations 
of GDNF, suggesting that some of the chronic effects of riluzole could be irreversible or 
take a very long time to reverse.  
Riluzole readily crosses the blood brain barrier and in addition to stimulate trophic factor 
production in glial cells, it has direct effects on motor neurons and maybe other yet 
unknown protein synthesis-dependent effects. Optimizing the administration protocols 
could avoid potential negative chronic effects such as the decrease of trophic factors 
levels described here.  In addition, it is possible that the modest effects of riluzole in ALS 
are due to a combination of acute protective effects and chronic negative effects. 
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However, this biphasic effect may be actually beneficial in other conditions such as 
spinal cord injury.  The initial protective effect of riluzole could help neuronal survival 
and axon growth through the damaged area. The secondary inhibition of trophic factor 
production might allow axons to leave the damaged area and reach their targets, thus 
reversing the damage. Optimizing the administration conditions for riluzole would 
depend on the pathology to be treated and the development of good peripheral markers of 
riluzole action in the central nervous system to adjust dosage according to the response of 
the patient.  
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CHAPTER 5: GENERAL DISCUSSION 
The inability of neurons to replicate makes their loss particularly devastating to the 
nervous system as new cells cannot be generated to replaced lost ones.  Therefore the 
nervous system has unique mechanisms to maintain motor neuron survival.   The inability 
of motor neurons to initiate a stress response appears counter intuitive in this context.  
Consequently, the role of heat shock chaperones has been extensively studied as a 
potential therapeutic target in neurodegeneration (Bruening, Roy et al. 1999; Batulan, 
Shinder et al. 2003; Robinson, Tidwell et al. 2005; Batulan, Taylor et al. 2006; 
Gifondorwa, Robinson et al. 2007; Robinson, Gifondorwa et al. 2010).  We have shown 
that Hsp90 plays a critical role in motor neuron survival due to its repressive effects on 
the purine receptor P2X7 (P2X7R).  Activation of P2X7R leads to inhibition of the 
PI3K/AKT pathway and Fas mediated apoptosis.  The atypical stress response may be 
due to the repressive effects of Hsp90 on P2X7R.  Removal of Hsp90 from this 
repressive complex under conditions of stress, would lead to motor neuron death.   
Significant motor neuron death is found at disease onset and increases as disease 
progresses in transgenic mutant SOD animals models (Bruijn, Becher et al. 1997) 
(Vinsant, Mansfield et al. 2013).  However the mechanism behind mutant SOD toxicity 
remains to be identified.  We show that mutant SOD facilitates nitration of Hsp90.  
Nitrated Hsp90 has been shown to activate P2X7 leading to cell surface expression of 
FasL and subsequent activation of FasR without transcriptional activation of Fas (Franco, 
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Ye et al. 2013). This suggests that mutant SOD facilitated Hsp90 nitration may be 
inducing motor neuron cell death by the same mechanism.  These findings explain why 
P2X7R inhibitors are protective in animal models for ALS (Apolloni, Amadio et al. 
2014).  However motor neuron cell death induced following inhibition of Hsp90 involves 
a slightly different mechanism.  Inhibition of Hsp90 leads to inhibition of the PI3K/AKT 
pathway and subsequently induces FasL expression.  This difference provides evidence 
for a toxic gain of function for nitrated Hsp90. 
ALS pathology has been attributed to both a cell autonomous and non-cell autonomous 
processes.  Transgenic animals containing genetic deletion of neuronal mutant SOD still 
develop the disease (Boillee, Yamanaka et al. 2006).  This suggests a glial contribution to 
disease pathology.  Conditioned media and co-culture experiments indicate that 
astrocytes secrete a soluble factor that induces motor neuron death (Pehar, Cassina et al. 
2004; Nagai, Re et al. 2007; Aebischer, Cassina et al. 2010; Diaz-Amarilla, Olivera-
Bravo et al. 2011; Basso, Pozzi et al. 2013; Re, Le Verche et al. 2014).  Therapeutic 
targeting of these cells to secrete trophic factors is a potential therapeutic treatment for 
ALS.  We show that acute treatment with riluzole induces trophic factor production in 
astrocytes and Schwann cells.  Therefore, treatment with riluzole could prevent the toxic 
effects observed of glial cells in ALS.  However, long-term treatment with riluzole 
reduces trophic factor levels to equal or below untreated cell types.  Therefore the current 
dosing regimen of twice a day for ALS patients could be detrimental in the long-term.  
Discontinuous riluzole treatment in animals can maintain elevated levels for trophic 
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factors and prevent trophic factor reduction in a factor specific manor.  This suggests that 
optimizing a discontinuous riluzole treatment in ALS patients may extend lifespan in 
ALS patients. 
Nitrated Hsp90 has been implicated in other disease states including spinal cord injury 
(Franco, Ye et al. 2013).  The ability of a normal cell to induce nitration of Hsp90 
suggests a signaling capability of this modification.  Therefore it could be possible for 
Hsp90 to be nitrated in circumstances that does not involve mutant SOD.  One such 
instance is in cases of sporatic ALS, where the cause of motor neuron disease is unrelated 
to genetics.  Certain stress related triggers, such as metal depleted wild type SOD 
(Rotunno and Bosco 2013), may induce Hsp90 nitration leading to motor neuron death 
and ALS pathology.  Therefore nitration of Hsp90 may explain disease pathology in ALS 
cases with unknown cause. 
In summary, we have identified Hsp90 and P2X7R as critical proteins in the regulation of 
motor neuron survival and cell death.  Mutant SOD facilitates Hsp90 nitration, which is 
known to induce P2X7R mediated cell death, an effect that may explain mutant SOD 
toxicity.  Selective therapeutic targeting of nitrated Hsp90, and not the form of Hsp90 
responsible for P2X7R repression, is a potential therapeutic target for drug development 
for the treatment of ALS.  Finally we have provided proof of principle that changes in the 
administration frequency of riluzole may improve therapeutic efficacy of the drug.  We 
have provided significant advances in causality of ALS and new therapeutic approaches. 
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APPENDIX A: FIGURES 
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Figure 1:  Effect of Hsp90 inhibition on neuronal survival.  
Cells were plated in the presence or absence of trophic factors for 24 h prior to geldanamycin treatment.  
Cell survival was measured using calcein-AM staining. (A) Motor neurons were treated with geldanamycin 
(GA, 0.01 nM - 500 nM) in the presence (, +TF) or absence of trophic factors (, -TF) for 24 h. (B) 
Representative images of motor neuron cultured in the presence of trophic factors 24 h after addition of 
geldanamycin (0.1 to 10 nM). The motor neurons were stained with calcein-AM and the images were 
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captured with a Plate Runner HD (Trophos). (C) Cells from whole embryo ventral spinal cords () and 
isolated cortical neurons (CN) at high (Δ) or low () density were treated with geldanamycin (0.1 nM – 10 
uM) for 24 h. (D) Representative images of cortical neurons 24 h after addition of geldanamycin (0.1 to 10 
nM). (E) Undifferentiated () and differentiated cells () NSC34 cells were treated with geldanamycin (0.1 
M - 100 M) for 24 h. (F) Levels of Hsp90 were compared in rat tissue including adult liver (Li), adult 
(Ad) and embryonic (Em) brain (Br), spinal cord (Sc), plated (Pl) and unplated (UN) motor neurons (MN) 
and the NSC34 motor neuron hybrid cell line (CL) by infrared western blot.  (G) Quantitation of Hsp90 
levels respect to β-actin.  (A-C) Data was fit to a sigmoidal curve, p < 0.0001.  Columns represent the mean 
 SD of at least 3 independent experiments. 
 
Figure 2:  Hsp90 inhibition induces Fas-dependent motor neuron apoptosis.  
(A) Cells were treated with 0.5 nM geldanamycin and 1 g/ml Fas:Fc, and compared to corresponding 
control (CTL).  The data was analyzed using 2-way ANOVA followed by Bonferroni post-hoc test, *p < 
0.05 versus CTL, **p < 0.05 versus CTL+TF. (B) Motor neurons cultured in the presence of trophic factors 
were treated with geldanamycin (0.01 nM – 500 nM) in the absence () or presence of 1 g/ml Fas:Fc () 
for 24 hours and then stained with Calcein-AM.  Data was normalized to control and fit to sigmoidal 
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curves.  The R
2
 for the curves was 0.87 for geldanamycin and 0.76 for geldanamycin + Fas:Fc. The EC50 
values for the curves (0.4 nM and 5nM respectively) were significantly different with p<0.0001.  (C) Motor 
neurons were treated with 0.5 nM geldanamycin and either 10 g/ml actinomycin D or 10 g/ml 
cycloheximide for 24 h. Motor neuron survival was assessed by calcein-AM staining and normalized to the 
control (CTL). *p < 0.05 versus control by 2-way ANOVA followed by Bonferroni post-hoc test. (D, E) 
Quantitative RT-PCR for Fas L (D) and Fas receptor (E) normalized to -actin. Messenger RNA was 
extracted from motor neurons treated with 0.5 nM geldanamycin for 18 h. Expressed as relative expression 
to untreated control (n=3). *p < 0.05 versus control by 1-way ANOVA followed by Bonferroni post-hoc 
test. (F) Motor neurons were treated with 0.5 nM geldanamycin and 50 M of the following caspase 
inhibitors: NCTL (negative control), Z-VAD (pan), Z-DEVD (caspase 3), Z-IETD (caspase 8), and Z-
LEHD (caspase 9) and compared to corresponding control (CTL).  Motor neuron survival was assessed by 
calcein-AM staining and normalized to the control. Statistical analysis was performed using 2-way 
ANOVA followed by Bonferroni post-hoc test, *p < 0.05 versus CTL, **p<0.05 versus TF+GA CTL. 
Columns represent the mean  SD of at least 3 independent experiments. 
 
Figure 3:  Geldanamycin (GA) induced cell death is independent of oxidative stress. 
Motor neurons were cultured in the presence of trophic factors and 0.5 nM geldanamycin or in media 
without trophic factors (TFD, positive control) and in the presence or absence of either 100 M L-NAME 
(A), 50 M MnTBAP or 50 M FeTCPP (C), or 5 M of the p38 MAPK inhibitor SB203580 (D) for 24 h. 
(B) Motor neurons were cultured in the presence of trophic factors and geldanamycin (0.001-100 nM) and 
in the absence () or presence () of 20 M DETANONOate for 24 h.  Data was fit to a sigmoidal curve, 
and values represent the mean  95% CI.  Motor neuron survival was assessed by calcein-AM staining and 
normalized to control. Statistical analysis was performed using 2-way ANOVA followed by Bonferroni 
post-hoc test, *p<0.05 versus control, **p<0.001 versus TFD. Columns represent the mean  SD of at least 
3 independent experiments.   
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Figure 4:   Inhibition of Hsp90 induces FOXO3a transcription factor activation and 
nuclear translocation.  
(A) Representative infrared western blot for total Foxo3a and phosphorylated FOXO3a(S253) from motor 
neurons treated with 0.5 nM geldanamycin (GA) for 16 hours. Band intensity was quantified and ratios of 
FOXO3a(Ser253) versus total FOXO3a (B) and FOXO3a versus GAPDH (C) were calculated. (D) 
Representative inmmunofluorescence of motor neurons transduced with an adenoviral vector expressing 
FOXO3a. Cells were cultured for 72 h and then cultured in the presence of 0.5 nM geldanamycin for 
additional 16 h. (E-G) Motor neurons were transduced with lentiviral particles expressing luciferase under 
the control of fork head response element (FHRE) for 24 h.  Cells were then cultured with 0.5 nM 
geldanamycin for 16 h prior to assessing luciferase activity (E) and motor neuron survival with calcein-AM 
staining (F). Columns represent the mean  SD of at least 3 independent experiments. Statistical analysis 
was performed using a student t-test, *p < 0.05 vs CTL. 
 65 
 
Figure 5: Inhibition of PI3K/AKT pathway induces cell death via FAS. 
Motor neurons were treated with either 10 M LY294002, 10 M Wortmannin or 0.5 nM geldanamycin  in 
the presence or absence of Fas:Fc for 24 hours and stained with Calcein-AM. Data was normalized to the 
corresponding control (CTL). Values are the mean ± SD of at least 3 independent experiments performed 
by triplicate.  The results were analyzed using 2-way ANOVA followed by Bonferroni multiple comparison 
test. *p<0.001 versus control.  
 
Figure 6: Hsp90 inhibition reduces AKT phosphorylation. 
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(A-D) Representative infrared western blots for total Akt, phospho-Akt(Ser 473), phospho-Akt(Thr 308), 
PDK1 and GAPDH from motor neurons treated with 0.5 nM geldanamycin for 24 h.  Band intensity was 
quantified and ratios of pAkt(Ser473) vs. total Akt (A), pAkt(Thr308) vs. total Akt (B), total Akt vs. 
GAPDH (C), and PDK1 vs. GAPDH (D) were calculated.  Values are the mean ± SD of at least 3 
independent experiments.  Results were analyzed by 1-way ANOVA followed by Bonferroni post-hoc test. 
*p<0.05 versus respective control. 
 
Figure 7:  Hsp90 inhibition induces apoptosis by PTEN mediated inhibition of the 
PI3K/AKT pathway.  
(A) Motor neurons were transduced with adenoviral vectors expressing GFP alone, or co-expressing GFP 
and either constitutive active PI3K, PDK1 or constitutive active Akt.  Seventy-two hours later GFP positive 
cells were counted (t=0) prior to media replacement with either 0.5 nM geldanamycin (GA) or trophic 
factors alone for additional 24 h.  Data was normalized to t=0.  Values are the mean ± SD of at least 3 
independent experiments performed by quadruplicate. Results were analyzed by 2-way ANOVA followed 
by Bonferroni post-hoc test. *p < 0.001 versus GA-treated GFP, **p < 0.05 versus GFP. (B) Expression of 
the recombinant proteins PI3K, PDK1 and Akt was confirmed by infrared western blot for myc-tag. (C) 
Motor neurons were incubated with 0.5 nM geldanamycin for 24 h in the absence or presence of the PTEN 
inhibitor, VO-OH(pic) (VOOH, 2 μM) or 48 h after transducing with PTEN or scrambled shRNA lentiviral 
particles. Cells were counted and normalized to control. *p < 0.05 versus respective control, **p<0.05 
versus respective control+GA by 1-way ANOVA followed by Bonferroni post-hoc test.  (D) 
Downregulation of PTEN expression by PTEN shRNA was confirmed by infrared western blot 48 h after 
motor neuron transduction and normalized to p75 receptor. Columns represent the mean  SD of at least 3 
independent experiments. 
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Figure 8:  Hsp90 inhibition activates P2X7 receptor. 
Motor neurons were incubated with 0.5 nM geldanamycin (GA) in the absence or presence of either P2X7 
inhibitor Brilliant Blue G (BBG, 10 μM), apyrase (APY, 1 U/mL) or the calcium chealator BAPTA-AM (1 
μM) for 24 h (left). Alternatively, cells were transduced with P2X7 receptor or scrambled shRNA lentiviral 
particles for 48 h and then cultured in the presence of 0.5 nM geldanamycin for additional 24 h (right). 
Survival was assessed by calcein-AM staining and normalized to control. *p < 0.05 versus GA by 1-way 
ANOVA followed by Bonferroni post-hoc test. Columns represent the mean  SD of at least 3 independent 
experiments.  
 
Figure 9:  Inhibition of Hsp90 induces motor neuron cell death via P2X7/PTEN 
dependent pathway. 
- -
B
BG AP
Y
BA
PT
A -
S
cr
 s
hR
N
A -
S
cr
 s
hR
N
A
P2
X
7 
sh
R
N
A
0
25
50
75
100
125
150
%
 M
o
to
r 
N
e
u
ro
n
 S
u
rv
iv
a
l 
*
*
* *
** **
**
+ GA+ GA
 68 
 
Figure 10:  Spinal motor neurons of ALS patients contain NO2Hsp90 
Transverse section of post mortem spinal cord from control and ALS patient immunostained for glial 
fibrillary acidic protein (GFAP, red) and nitrated Hsp90 (NO2Hsp90, green).  Images were obtained using 
confocal microscopy.  Dotted lines correspond to motor neurons. 
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Figure 11: NO2Hsp90 is detected in G93A mice spinal cord during symptomatic 
phase. 
(A) Nontransgenic (NonTg), wild type SOD transgenic (wt hSOD1), asymptomatic (p60), early 
symptomatic (p90), and symptomatic (p120) mutant G93A transgenic animals (hSOD1
G93A
) were 
transcardial perfused. 30-40 μm transverse sections of ventral spinal cord were immunostained for glial 
fibrillary acidic protein (GFAP, red) and nitrated Hsp90 (NO2Hsp90, green) and imaged using confocal 
microscopy (dotted lines).  (B) Spinal cord homogenate (40 μg) was separated by SDS-PAGE and 
immunoblotted for nitrated Hsp90 (NO2Hsp90) and Hsp90.  Band intensities were quantified and normalize 
to B-actin.  (C) Cortical and spinal astrocytes were treated with peroxynitrite for 1 min and 24 hours.  Cell 
lysate were then prepared and separated by SDS-PAGE and immuoblotted for NO2Hsp90 and β-actin.  
Peroxynitrite-treated cell lysate (in vitro) was included as a control. 
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Figure 12:  Zinc deficient and Quad mutant SOD. 
Peroxynitrite (0.5 mM) was added to brain homogenate (1 mg/ml) in the presence or absence of either wild 
type (Wt, blue), zinc deficient (Zn-, green) or quad (Q, purple) SOD (1 mg/mL).  Following brief 
vortexing, samples were separated on a SDS-PAGE and immunoblotted for nitrotyrosine (NO2Tyr, green), 
nitrated Hsp90 (NO2Hsp90, red), Hsp90 (green) and GAPDH (red). (A) Lane intensity of NO2Tyr was 
normalized to GAPDH and (B) band intensity of NO2Hsp90 was normalized to Hsp90. Statistical analysis 
was performed using 1-way ANOVA followed by Bonferroni multiple comparison’s test. * p<0.05 vs Wt. 
 71 
 
Figure 13: Quad mutant SOD-induced motor neuron death requires copper-
mediated oxidative signaling.  
(A and B) Wild type (Wt, blue), zinc deficient (Zn, green), quad mutant (Q, purple) and copper deficient 
(Cu) SOD was delivered to motor neurons using the cell permeant agent chariot in the absence (A) or 
presence (B) of  50 μM bathocuprione.  After 24 h in culture motor neurons were counted by hand or 
stained using Calcein AM.  Data normalized to chariot control. Statistical analysis was performed using one 
way ANOVA followed by Bonferroni multiple comparison’s test. * p<0.05 vs Wt. ** p<0.05 vs Q. *** 
p<0.05 vs Zn.  (C) Motor neurons were fixed 16 h following Wt, Zn, and Q SOD intracellular delivery and 
immunostained for NO2Hsp90 (red) and Hsp90 (green). DAPI was used as nuclear staining. (D) Motor 
neurons were treated as described in A in the presence or absence of 100 M L-NAME, 50 M FeTCPP, or 
50 M MnTBAP immediately following chariot delivery.  After 24 h in culture motor neurons were 
counted by hand or stained using Calcein AM.  Data normalized to chariot control. Statistical analysis was 
performed using one way ANOVA followed by Bonferroni multiple comparison’s test. * p<0.05 vs Wt. ** 
p<0.05 vs Q. *** p<0.05 vs Zn. 
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Figure 14:  Nitrotyrosine is detected in spinal cord from Quad mutant SOD 
transgenic mice. 
Quad and G93A transgenic mice were transcardial perfused. 30-40 μm transverse ventral spinal cord 
sections were immunostained for human SOD (hSOD), glial fibrillary acidic protein (GFAP), nitrotyrosine 
(NO2Tyr, green) and Nissl (blue) and imaged using confocal microscopy. 
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Figure 15:  Riluzole induces cardiotrophin-1 production in astrocytes and Schwann 
cells.   
Confluent astrocytes (A) were treated with riluzole for 24 h, RNA was extracted and the levels of CT-1, 
BDNF and GDNF were quantified, normalized against -actin and expressed as relative levels respect to 
untreated cells.  Conditioned media from astrocytes (B) and Schwann cells (C) was obtained by incubating 
the cells in the presence or absence of riluzole for 24 h, replacing the media and leaving the cells to 
condition the fresh media in the absence of riluzole for additional 24 h. Motor neurons were plated in the 
presence of the trophic factors BDNF, GDNF, and CT-1 (TF) or in the absence of trophic factors (trophic 
factor deprivation, TFD). When indicated, trophic factor-deprived motor neurons were plated in the 
presence of 1/10 dilution (A) or 1/25 dilution (C) of either untreated conditioned media (CM) or riluzole-
conditioned media (RCM) and in the presence or absence of neutralizing antibody against CT-1 (Anti CT-
1), BDNF (Anti BDNF) and GDNF (Anti GDNF). Motor neurons were cultured for 3 d then counted by 
hand or using Calcein AM. Confluent Schwann cells (D) were treated with riluzole for 24 h, RNA was 
extracted and the levels of CT-1, BDNF and GDNF were quantified as described in A.  Values are the 
mean of at least 3 experiments. For B and C, *p<0.05 vs TFD, **p<0.05 vs RCM,  *** p<0.05 vs CM.  For 
A and D, *p<0.05 vs BDNF or GDNF. Statistical analysis was performed using one-way ANOVA 
followed by Bonferroni post-test. 
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Figure 16:  Chronic riluzole treatment reduces trophic factor production in 
astrocytes and Schwann cells.  
Motor neurons were plated in the presence (TF) or absence of trophic factors (TFD), or with media 
conditioned by astrocytes (A) or Schwann cells  (B) for the indicated periods of time (white arrows).  
Riluzole was then replaced with new media without riluzole and 24 h later conditioned media was collected 
(black arrows).  (A) Motor neurons were plated with conditioned media from astrocytes cultured in the 
absence of riluzole for one (UN) or 6 days (6U) or presence of riluzole for 24 h (1R) or 6 days (6R), or 
cultured for 5 days prior to 24 h incubation with riluzole (5U1R).  Motor neurons were cultured for 3 days 
in the conditioned media then counted by hand or using Calcein AM.  (B) Motor neurons were plated in 
conditioned media from Schwann cells and cultured in the absence of riluzole for one day (UN) or 3 days 
(3U) or presence of riluzole for 24 h (1R), 3 days  (3R), and for 2 days and then treated with riluzole for 24 
h (2U1R).  Motor neurons were cultured for 3 days in described conditioned media then counted by hand or 
using Calcein AM.  (C) Astrocytes were incubated without (0) or with riluzole for 24 h (1) and 6 days (6) 
before RNA was extracted.  The relative changes in mRNA expression of CT-1 (red) BDNF (yellow) and 
GDNF (green) were determined using -actin to normalize.  (D) Schwann cells were incubated without (0) 
or with riluzole for 24 h (1) and 3 days (3) before determining the relative changes in mRNA expression of 
CT-1 (red) BDNF (yellow) and GDNF (green) were determined as described in C.  Values are the mean ± 
SD of at least 3 independent experiments.  For A and B, statistical analysis was performed using ANOVA 
followed by Bonferroni multiple comparison’s test, *p<0.05 vs TFD, **p<0.05 vs 1R, *** p<0.005 vs UN. 
# p<0.05 vs 6U.  For C and D, *p<0.05 vs. 0 day riluzole, **p<0.05 vs. 1 day riluzole. 
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Figure 17:  Effects of riluzole on the trophic factor levels in vivo.   
Male C57BL/6J mice were treated with riluzole (100 µg/ml) in the drinking water for the periods indicated 
in the figures.  At the indicated times the mice were sacrificed, the tissues harvested and stored at -80°C.  
Spinal cord (A) sciatic nerve (B) and brain (C) were homogenized and CT-1 (red), GDNF (green) and 
BDNF (red) protein levels were quantified by ELISA.  Values are the mean of at least three animals from at 
least two independent studies performed by duplicate.  Statistical analysis was performed using 1-way 
ANOVA followed by Bonferroni multiple comparison’s test, * p<0.001 vs control **p<0.05 vs 15 days 
 
 
Figure 18:  Discontinuous treatment of riluzole maintains higher levels of trophic 
factors.   
(A) Riluzole treatment schedule. Animals were administered riluzole (grey arrows) in their drinking water 
(100 µg/ml) continuously for 15 or 30 days then riluzole was removed for another 15 days before receiving 
a second dose of riluzole for additional 6 or 15 days. At the indicated time points the mice were sacrificed 
(x), the tissues  were harvested and stored at -80°C.  Spinal cord was homogenized and CT-1 (B), GDNF 
(C) and BDNF (D) concentrations were quantified by ELISA.  Values are the mean of at least 4 mice with 
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the determinations performed by duplicate.  Statistical analysis was performed using ANOVA followed by 
Bonferroni post-test. * p<0.001 vs control **p<0.05 vs 15 days, #p<0.05 vs 3 days, ## p<0.05 vs 30 days. 
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Table 1:  EC50 of different cell types treated with geldanamycin 
Cells were treated with geldanamycin (0.01 nM to 100 µM) for 24 hours.  Cell survival was measured 
using calcein-AM staining as described in material and methods. Values represent the mean and 95% CI of 
at least 3 independent experiments.  Data was fit to a sigmoidal curve, p < 0.0001. 
  
Cell Type EC50  
(95% CI) 
Ratio to Motor 
Neurons + TF 
R
2 
Motor Neuron +TF 0.5 nM  
(0.4 nM to 0.6 nM) 
1 0.89 
Motor Neuron - TF 3.4 nM  
(2.4 nM to 4.8 nM)  
7 0.74 
Embryo Ventral 
Spinal Cord 
146 nM  
(118.3 nM to 180.3 nM) 
292 0.84 
High Density Cortical 
Neurons 
5.9nM  
(4.95 nM to 7.1 nM) 
12 0.94 
Low Density Cortical 
Neurons 
497.6 nM  
(404.8 nM to 611.7 nM) 
995 0.80 
NSC34 
undifferentiated 
7.75 µM  
(6.1 µM to 9.8 µM) 
15500 0.82 
NSC34 
differentiated 
0.70 µM  
(0.4 µM to 1.2 µM)  
1400  0.65  
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Table 2:  Metal deficient SOD binds Hsp90. 
Dissociation constants (KD) for wild type (Wt), zinc deficient (Zn), copper deficient 
(Cu), and copper/zinc deficient SOD (APO) binding to Hsp90 were determined using 
surface plasmon resonance (SPR). Increasing concentrations of wild type and mutant 
SOD were passed over immobilized Hsp90 to calculate the KD (nM). 
 
 
KD 
WT 0.0 
Zn 80.5 
Cu 75.0 
APO C111S 70.3 
 
 
 80 
APPENDIX C: SUPPLEMENTAL FIGURES 
  
 81 
 
 
Supplemental Figure 1:  Optimization of experiments conducted in Schwann Cells 
Conditioned media from Schwann cells (A) was obtained by incubating the cells in the presence or absence 
of riluzole for 24 h, replacing the media and leaving the cells to condition the fresh media in the absence of 
riluzole for additional 24 h.  Motor neurons were plated in the presence of the trophic factors BDNF, 
GDNF, and CT-1 (TF) or in the absence of trophic factors (trophic factor deprivation, TFD). When 
indicated, trophic factor-deprived motor neurons were plated in the presence of indicated dilution of either 
untreated conditioned media (CM) or riluzole-conditioned media (RCM) for three days.  Motor neuron 
survival was determined by counting by hand. B) Motor neurons were cultured in the presence of a 1/25 
dilution of untreated and riluzole treated conditioned media with or without neutralizing antibody against 
BDNF (Anti BDNF) and GDNF (Anti GDNF). Cells were cultured for 3 d then counted by hand.  C) Motor 
neurons were plated with conditioned media from Schwann cells incubated in absence (UN) or with 
riluzole for 24 h (1R), 6 days (6R), or cultured for 5 d the before incubation with riluzole for 24 h 
(5U1RD). D)  Schwann cells were treated with riluzole for one, three and six days.  RNA was extracted and 
relative levels of CT-1, BDNF and GDNF were quantified (normalized using -actin). 
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Supplemental Figure 2:  Riluzole treatment does not affect cell morphology. 
Confluent astrocytes and Schwann cells cultured in the absence (A) or presence of riluzole for 24 h (B) or 3 
days for Schwann cells (C) or 6 days for astrocytes (C).  
  
Schwann Cells Astrocytes
A
B
C
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